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Chapter 1: Introduction 
This dissertation is divided into three chapters. Chapter 1 provides the rationale for and 
background information on the dietary intervention study conducted in Moshi, Tanzania, 
2013/14. This study was part of the project “A better bitter gourd: Exploiting bitter gourd to 
increase incomes, manage type 2 diabetes, and promote health in developing countries” which 
was coordinated by the AVRDC-The World Vegetable Center in Taiwan. Chapter 2 includes 
information on a cross-sectional survey which was conducted as part of the bitter gourd project 
in 2011 among diabetic patients in the same research area. Chapter 3 and following sections 
describes the intervention study and its recruitment procedure followed by their discussion. 
1.1 Emerging epidemic of pre-diabetes and diabetes in low- and middle-income 
countries 
Some non-communicable diseases such as type 2 diabetes mellitus type, are major health 
problems, not only in high-income, but also in low- and middle-income countries (WHO 2014). 
Type 2 diabetes mellitus is a disease which is partially linked to overweight and obesity as well 
as to low physical activity (Popkin et al. 2012; WHO 2014; Go et al. 2013; Boutayeb et al. 2005). 
Numbers of people living with diabetes are high and expected to further increase within the 
next decades (Figure 1).  
 
Figure 1 Estimated number of people (20-79 years) with diabetes per region in 2015 and 2040 
(IDF 2015) 
Introduction 
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Diabetes is defined as fasting plasma glucose (FPG) ≥7.0 mmol/L (126 mg/dL) or 2-h plasma 
glucose ≥11.1mmol/l (200mg/dl) (WHO et al. 2006). In the age group of 20-79 years, the current 
estimate of the global prevalence of diabetes is 8.8%, with an expected increase to 10.4% by 
2040. In Sub-Saharan Africa, the current estimate of the regional prevalence is 3.2% with an 
expected increase to 4.2% by 2040. It is assumed that almost 67% of diabetes cases are still 
undiagnosed in this region (IDF 2015). In Sub-Saharan Africa, including the United Republic of 
Tanzania, 90% of all cases are type 2 diabetes mellitus (Levitt 2008). The International Diabetes 
Federation (IDF) estimated Tanzania’s national diabetes prevalence to be 2.3% in 2011 (IDF 
2012), 7.8% in 2013 (IDF 2013), and 3.5% in 2015 (IDF 2015). Other studies showed diabetes 
rates ranging from 0.6% to 5.8% (Kavishe et al. 2015; Aspray et al. 2000). Prevalence of pre-
diabetes, defined as impaired glucose tolerance (IGT), were 10.6% in 2011 (IDF 2012) and 9.1% 
in 2013 (IDF 2013). 
1.2 Pre-diabetes  
Pre-diabetes refers to a dysglycemic state which lies between normal glucose regulation and 
diabetes (Perreault et al. 2014). Pre-diabetic states are mostly defined according to FPG and 2-h 
glucose concentrations and are categorized into isolated impaired fasting glucose (IFG), isolated 
IGT, or combined IFG and IGT. Cut-off values for IGT are 7.8-11.0 mmol/L (140-199 mg/dL) for 2-
hour glucose levels measured during an oral glucose tolerance test (OGTT) with a 75 g glucose 
load (WHO 1999; ADA 2010). Different cut-off values are used to define isolated IFG. Values 
recommended by the World Health Organization (WHO) are 6.0-6.9 mmol/L (WHO et al. 2006) 
and those recommended by the American Diabetes Association (ADA) are 5.6-6.9 mmol/L (ADA 
2010). The ADA also recommends the use of HbA1c to define pre-diabetes with cut-off values of 
5.7-6.4% (39-46 mmol/mol) (ADA 2010). Metabolic defects such as insulin resistance, beta cell 
dysfunction, and ectopic fat accumulation which lead to IFG or IGT and can further progress to 
type 2 diabetes mellitus are presented in Table 1, p.13 (Perreault et al. 2014).  
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Table 1 Metabolic defects in impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT) (Perreault et al. 2014) 
 Isolated 
IFG 
Isolated 
IGT 
Combined 
IFG and IGT 
Insulin resistance    
  Reduced peripheral glucose disposal 
      (Abdul-Ghani et al. 2008; Ahrén et al. 1997; Færch et al. 2009;     
      Kantartzis et al. 2010; Li et al. 2013; van der Zijl et al. 2010) 
– + ++ 
  Increased hepatic glucose production 
         (Abdul-Ghani et al. 2008; Kantartzis et al. 2010; Li et al. 2013; Perreault et al.  
         2010; van der Zijl et al. 2010) 
+ – + 
Beta cell dysfunction    
  Defective absolute insulin secretion 
         (Abdul-Ghani et al. 2008; Li et al. 2013; van der Zijl et al. 2010) 
+ – ++ 
  Defective relative insulin secretion 
         (Fritsche et al. 2000; Laakso et al. 2007; Li et al. 2013; Nauck et al. 2010; van  
         der Zijl et al. 2010) 
+ ++ ++ 
Ectopic fat accumulation    
  Increased fat content in the liver 
         (Alssema et al. 2013; Henkel et al. 2005) 
+ ++ +++ 
  Increased fat content in skeletal muscle 
         (Vollmer et al. 2008) 
+ + + 
“+” and “–“ indicate whether the condition is present in the different pre-diabetic subtypes in 
relation to individuals with normal glucose regulation. The number of “+” and “–“ indicate the 
severity of the conditions  
Pre-diabetes can be detected during a screening at clinical visits or public screening activities in 
communities. Different screening methods may be applied individually or in combination, 
depending on the purpose and scope of the screening. Such methods include questionnaires, 
measurement of FPG, random blood glucose (RBG), HbA1c, or conduction of an OGTT test. A 
screening can be performed in stages, starting, for example, with using a questionnaire to 
assess risk factors, followed by an assessment of the glycemic status of those with elevated risk 
factor scores. The ADA recommends a screening every three years for asymptomatic adults 
older than 45 years of age and for younger adults with a BMI ≥25 kg/m² who have at least one 
additional risk factor such as physical inactivity or a first-degree family member with diabetes 
(ADA 2014). However, some argue that screening for diabetes mellitus and pre-diabetes is not 
justifiable (Diabetes Care 2002), as it does not meet all criteria for disease screening (National 
Cancer Control Policy Australia 2015; Wilson, J. M.G. et al. 1968).   
Introduction 
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Although pre-diabetes does not always progress to type 2 diabetes mellitus, up to 25% of cases 
do so within three years after diagnosis (Nichols et al. 2007). In Tanzania, the management and 
treatment possibilities for diabetes are insufficient (Ministry of Health and Social Welfare, 
Tanzania 2013; Peck et al. 2014a; Robertson et al. 2015). Thus, prevention of diabetes is one 
way to reduce the socioeconomic burden that arises from increases in prevalence and 
uncontrolled diabetes (Wyne 2008). In addition to lifestyle interventions, which have been 
shown to positively influence glucose metabolism (Jenkins et al. 2011; Samjoo et al. 2013), 
medicinal plants with anti-diabetic properties (Khan et al. 2012; Parikh et al. 2014; Tag et al. 
2012; Yakubu et al. 2015) might be used to lower raising blood glucose levels and, thus, to 
prevent or delay the onset of diabetes. 
1.3 Phytomedicine: Momordica charantia  
In regard to the increasing rates of diabetes mellitus and pre-diabetes as well as lack of 
sufficient diabetes care described in chapter 1.2, alternative strategies to lower glucose levels 
and to prevent or delay the onset of diabetes may be explored. One alternative strategy to 
medical treatment is the use of plants with hypoglycemic properties (Grover et al. 2002; Joseph 
et al. 2013; Wang et al. 2013). Momordica charantia (Figure 2, p. 15), also known as bitter 
gourd, bitter melon, or balsam pear is a flowering vine pre-dominantly cultivated in Asian 
countries, but also available in African and South-American countries. In East Africa, it is mainly 
collected from the wild It belongs to the family of Cucurbitacae, has both female and male 
flowers, green leaves, and edible fruits which exhibit a bitter taste (Basch et al. 2003; Grover et 
al. 2004; Krawinkel et al. 2006). Unripe fruits can vary in size and color from white to dark 
green. Ripe fruits are inedible (Sathishsekar et al. 2005; Alam et al. 2015).  
Introduction 
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Figure 2 Bitter gourd plant grown in a private garden (left) and bitter gourd fruits purchased 
from the local center market an supermarket in Moshi 
Bitter gourd includes high amounts of vitamin A, C, E, B1, B2, B3, and folate. Further it includes 
high amounts of calcium, zinc, iron, and fiber, among others. Other compounds of bitter gourd 
which are also responsible for its bitter taste are phenols, terpenes such as saponins, and 
glucosinolates (RI et al. 2006; Snee et al. 2011).  Bitter gourd has not only been used for its 
hypoglycemic properties, but also against cancer, malaria, ulcer, dyslipidemia, and hypertension 
(Alam et al. 2015) with its anti-inflammatory, antiviral, and antibacterial properties (Budrat et al. 
2008; Joseph et al. 2013).  
 Anti-diabetic effects of extracts and isolated compounds of bitter gourd have been 
demonstrated in many animal studies in type one and type two diabetic rodents (Klomann et al. 
2010; Huang et al. 2008; Huang et al. 2013; Sridhar et al. 2008). Several human studies which 
have been conducted to assess hypoglycemic effects of bitter gourd supplementation resulted 
in different outcomes (Tongia et al. 2004; Dans et al. 2007; John et al. 2003; Zänker et al. 2012; 
Srivastava et al. 1993; Tsai et al. 2012; Welihinda et al. 1986; Fuangchan et al. 2011; Kochhar et 
al. 2011) and no clear recommendation on the application of bitter gourd variety, dosage, and 
mean of consumption could be made. However, usage of whole raw fruits may exhibit the 
highest potential of hypoglycemic effects (Habicht et al. 2014). The hypoglycemic effect of bitter 
gourd may be more of short term rather than cumulative (Platel et al. 1997)  
Knowledge on bitter gourd and diabetes 
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1.4 Objectives  
The main objective of the intervention study was to examine anti-diabetic effects of 2.5 g dried 
bitter gourd powder per day over the course of eight weeks among pre-diabetic study 
participants. The study aimed to examine differences between bitter gourd and placebo 
treatment in regard to FPG as the primary outcome. Detailed information on hypothesis and 
secondary outcomes is provided in chapter 3.1  
Chapter 2: Knowledge of bitter gourd and diabetes among diabetic patients in the 
Kilimanjaro Region, Tanzania 
2.1 Introduction 
Increasing diabetes prevalence implies increasing diabetes-related complications, including 
macro- and microvascular diseases such as retinopathy, foot ulcers, and nephropathy, as well as 
coronary heart problems (Fowler 2008). In a 2003 review, African populations were reported to 
have low rates of macrovascular disease, but the highest rates of microvascular diseases, 
compared to other populations. Microvascular complications might be linked to poor glycemic 
control due to inadequate access to, or high costs of, medical care, and late diagnosis of 
diabetes (Mbanya et al. 2003; Gill et al. 2008; Justin-Temu et al. 2009).  Chiwanga and Njelekela 
(2015) found that among diabetic patients in a setting in Dar es Salaam, 15% had foot ulcers, 
44% had peripheral neuropathy, and 15% had peripheral vascular disease. Forty-eight percent 
of the patients had received education on foot care, mostly from nurses (Chiwanga et al. 2015). 
Limited knowledge of diabetes among communities, diabetic patients, and health professionals 
was found in studies across the globe (Chiwanga et al. 2015; Sircar et al. 2010; Metta et al. 
2015; Sweileh et al. 2014; Kavishe et al. 2015; Guler et al. 2011). The current study aimed to 
assess knowledge of bitter gourd as an anti-diabetic plant as well as knowledge, burden, and 
management of diabetes among diabetic patients in the Kilimanjaro Region in Tanzania. 
Knowledge on bitter gourd and diabetes 
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2.2 Methods  
2.2.1 Study area  
The study was conducted in June and July 2011 at the diabetes clinics of the Kilimanjaro 
Christian Medical Centre (KCMC) in Moshi and the Machame Lutheran Hospital (MLH) in the Hai 
District. Both are located in the Kilimanjaro Region in northern Tanzania, which had a 
population of 1,640,087 people in 2012 (National Bureau of Statistics & Ministry of Finance 
2013). Moshi Municipality is the capital of the region and had 184,292 inhabitants in 2012. 
Machame is located approximately 15 km from Moshi Municipality on the slope of Mt. 
Kilimanjaro and had a population of about 67,000 in 2012 (National Bureau of Statistics, 
Ministry of Finance, et al. 2013; Machame Lutheran Hospital 2015b). Machame Lutheran 
Hospital is owned by the Evangelical Lutheran Church of Tanzania-Northern Diocese. The 
hospital serves a catchment area of the approximately 1.6 million people of the Kilimanjaro 
Region and has more than 22,000 outpatients per year. After malaria, diabetes is the second 
most common disease treated in the hospital (Machame Lutheran Hospital 2015b; Machame 
Lutheran Hospital 2009; Machame Lutheran Hospital 2015a). Kilimanjaro Christian Medical 
Centre is one of the four referral hospitals of Tanzania and serves a catchment area of 
approximately 11 million people in Northern Tanzania. KCMC has had a diabetes clinic since 
1996, which was visited by about 2,000 adult and 370 pediatric patients in 2014. There were 
three trained staff members, one examination room, and one consultation room (Kilimanjaro 
Christian Medical Centre 2015b; Kilimanjaro Christian Medical Centre 2015a).  
2.2.2 Objectives 
The objectives of this study were to assess knowledge on and usage of bitter gourd, bitter plants 
and phytomedicine among diabetic patients. It further aimed to assess knowledge, burden, and 
management of diabetes among the diabetic patients. The findings of this study will be used to 
suggest future interventions and research topics regarding diabetes in the region.  
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2.2.3 Study design and recruitment  
The current study was a cross-sectional survey. Adult patients were recruited through 
convenience sampling during clinic visits. Patients were informed on the purpose and procedure 
of the study prior to their regular checkup and asked to participate in this survey. At KCMC, 
patients came on Wednesdays and Fridays for regular checkups, during which nurses measured 
FPG, blood pressure (BP), and body weight. Medical counseling by a physician was offered on 
Wednesdays. At MLH, opening hours were on Tuesdays. Inclusion criteria were being over the 
age of 18 years, being a registered diabetic patient, and giving consent to participate in the 
study. This study was explorative, so no sample size calculation was applied. 
2.2.4 Data collection 
Standardized questionnaires with structured, semi-structured, and open-ended questions were 
administered in private areas of the hospitals by trained nurses in face-to-face interviews in 
Swahili, Tanzania’s national language (Figure 3, p. 19). Questionnaires were compiled in English 
forward and backward translated, and pre-tested among diabetic patients at KCMC. English 
versions of the questionnaires are given in the appendix (A-C). Demographic and socioeconomic 
status were recorded, along with age at diagnosis, type, family history, burden, management, 
and knowledge of diabetes. The burden of diabetes was assessed using open-ended questions 
in which patients were asked about complications and whether they had to give up something 
to pay for treatment. Management of diabetes was assessed with open-ended questions about 
the type of treatment and frequency of visits to a doctor. Knowledge was assessed using open-
ended questions about symptoms, complications, and causes of diabetes. Data on body weight 
and height were obtained from the medical files of the participants. Body mass index (BMI, 
kg/m²) was categorized by the following cut-off points: <18.5 (underweight), 18.5-24.9 (normal 
weight), 25.0-29.9 (overweight), 30.0-34.9 (obese class I), 35.0-39.9 (obese class II), and ≥40.0 
(obese class III) (WHO 2015; WHO 2004).  
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Figure 3 Interview setting; patients were shown pictures of bitter gourd to be able to 
recognize the fruit  
2.2.5 Statistics 
Data analysis was performed using SPSS versions 20 and 22 (SPSS Inc, Chicago Illinois). Results 
are expressed as average values, with mean and standard deviation (SD) used if data are 
consistent with a normal distribution and median and interquartile range (IQR) used if data are 
not consistent with a normal distribution, or as frequencies. A knowledge score was calculated 
for each participant from the total number of correctly named symptoms, complications, and 
causes. Scores were categorized using percentile ranges to represent little (5th-25th), medium 
(25th-50th), good (50th-90th), and very good (above 90th) knowledge. Differences were calculated 
for sex, insurant or non-insurant, farmer or non-farmer, and member or non-member of a 
diabetes support group. The two-sample t-test was used to compare means of normally 
distributed variables and the Mann-Whitney U-test was used to compare non-normally 
distributed continuous data. Categorical data was tested with the chi-squared test. Effect size 
was calculated using Rosenthal’s r. Correlations between variables were calculated using 
Spearman's rho. In all statistical tests, p<0.05 was considered statistically significant.  
2.2.6 Ethical considerations 
Ethical clearance was obtained from the Institutional Review Board of Kilimanjaro Christian 
Medical College. Further approval was obtained from the regional medical officer. Verbal 
consent was obtained from each participant prior to the interview, after explaining the 
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procedure and purpose of the study. Each participant was informed that he or she could 
withdraw at any time without consequences.  
2.3 Results  
2.3.1 Demographic and anthropometric profile of diabetic patients 
A total of 155 patients (53% female) were interviewed, all of African origin. Demographic and 
socioeconomic details of the participants are shown in Table 2, p.21. Median age was 57.0 
(46.8-65.0) years. The majority of patients were married and had at least primary education. 
The occupation varied between the patients. However, the plurality was a farmer or did farm 
field services. Males were older than females (Mdn=62.0 vs. Mdn=54.0, U=2159.5, z=-2.885, 
p=0.004, r=-0.232). Thirty-four percent of participants were farmers. Educational level was 
similar between sexes but was higher among farmers than non-farmers (Mdn=3 vs. Mdn=5, 
U=1717, z=-3.431, p=0.001, r=-0.277).  
 Mean BMI was higher among females (M±SD=27.8±5.0, SE: 0.56 kg/m²) than males 
(M±SD=25.5±3.4, SE: 0.40 kg/m²), (t(153)=3.335, p=0.001, r=0.26). In addition, BMI categories 
differed between sexes, with females having a higher prevalence in the obese categories 
(U=2235, z=-2.908, p=0.004, r=-0.234). There was no significant difference in BMI between 
farmers and non-farmers. BMI was positively correlated with age at diagnosis (rho=0.226, 
p<0.001). BMI classification for female, male, and all participants is shown in Figure 4. 
 
Figure 4 Distribution of BMI of overall, female, and male participants 
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Table 2 Demographic and socioeconomic data of participants 
 
 
  
Variable    n Overall Female Male 
Age in years  
[median, IQR] 
154 57.0  
(46.8 – 65.0) 
54.0  
(42.5 – 62.0) 
62.0  
49.5 – 69.0) 
Age in years at diagnosis  
[median, IQR] 
152 46.0 
(36.3 – 55.0)  
45.0  
(35.0 – 53.0) 
49.5  
(37.0 – 57-0) 
Body mass index [mean±SD] 155 26.74±4.5 27.8±5.0 25.5±3.4 
Marital status [%] 154    
Single  18 17 18 
Married  64 54 74 
Separated/divorced  2 4 0 
Widowed   17 25 8 
Religion [%] 155    
Christian  82 88 75 
Islam  18 12 25 
Educational level [%] 155    
No formal  2 2 1 
Few years primary  21 23 19 
Completed primary  26 33 19 
Few years secondary  7 5 8 
Completed secondary   8 5 12 
High school/still studying  36 32 40 
Occupational status [%] 155    
Artisan   4 2 5 
Business sector  14 12 16  
Farmer or farm labor 
service  
 34 35 32  
Housewife   6 11 0 
Service industry  10 7 14 
Student  5 5 5 
Teacher   14 21 7 
Retired  9 1 18  
Other  4 7 3 
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2.3.2 Knowledge and usage of bitter gourd among diabetic patients 
Only 7% have ever heard of bitter gourd, usually from neighbors, friends, or family members. 
Four percent did state they used bitter gourd to treat a disease, but did not further specify the 
disease. If bitter gourd was eaten, it was mainly consumed daily as juice, boiled, or cooked and 
mixed with other vegetables and purchased at the market. One patient of the pre-test specified 
the preparation of bitter gourd she was using for her diabetes. She squeezed the plant and 
mixed the juice with water and drank two cups per day. Of those who know bitter gourd, the 
majority have heard that bitter gourd is used to treat diabetes, while one patient had heard of 
its effect on hypertension. None of the patient stated to eat bitter gourd as a usual vegetable. 
Bitter gourd season could not be detected within this survey. However, bitter plants were 
consumed 90% of participants and around 50% said to know and use medicinal plants. A total of 
21 bitter plants and 44 medicinal plants were named. Most consumed bitter vegetables were 
hare lettuce and African nightshade. Most named treated diseases were hypertension, diabetes, 
cancer, and wounds. Almost all patients would eat specific vegetables with anti-diabetic effects, 
and would both grow them in their garden or purchase them.  
2.3.3 Individual burden of diabetes 
Median age at diagnosis was 46 years (36.3-55.0), with no significant difference between sexes. 
Farmers were older at diagnosis than non-farmers (Mdn=53.5 vs. Mdn=44.0, U=1717, z=-3.431, 
p=0.001, r=-0.275). The median number of years living with diabetes since diagnosis was 8.0 
(36.3-55), and was higher among males than females (Mdn=9.0 vs. Mdn=7.5, U=2263.5, z=-
2.389, p=0.017, r=-0.193).  
 Table 3 on p.23, shows symptoms perceived before diagnosis and current reported 
complications. The duration with which patients had symptoms before diagnosis ranged from 
one week (10%) to over ten years (1%). One patient perceived symptoms during pregnancy. 
Around 40% perceived symptoms between six months and one year prior to diagnosis. When 
patients were asked who else in their family had diabetes, 41% said a first-degree relative, 5% 
said a second-degree relative, 6% said both, and 3% said a spouse. Among the 28 participants 
who had to give up something to pay for medication and checkups, only seven were NHIF 
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members or received donations. Patients reported having to forego expensive clothing, 
luxurious or healthy food, and traveling to afford diabetic care.   
Table 3 Perceived symptoms of diabetic patients prior to diagnosis and reported 
complications 
Symptoms [%] Overall 
(n=155) 
  Complications [%] Overall 
(n=155) 
Frequent urination 87.7   Impaired sight 11.6 
Thirst 87.7   Blindness 4.5 
Weakness and fatigues 92.3   Impotence 8.4 
Tingling and/or numbness 68.4   Numbness 5.8 
Weight loss 4.5   Amputation 1.3 
Blurred vision 3.2  Hypertension 42.6 
 
2.3.4 Knowledge on diabetes 
Eight percent of patients knew they were type I diabetic, 17% knew they were type II diabetic, 
and 75% did not know their diabetes type. At least one symptom, complication, or possible 
cause could be named by 92%, 76%, and 45% of patients, respectively. Knowledge scores 
ranged from 0 to 11. Patients were categorized into groups having no or little knowledge (15%), 
medium knowledge (31%), good knowledge (44%), and very good knowledge (10%). Knowledge 
scores and categories did not differ between sexes or between members and non-members of a 
diabetes support group. Median knowledge scores among non-farmers were significantly higher 
than among farmers (Mdn=5 vs. Mdn=3.5, U=1955.5, z=-2.767, p=0.001, r=-0.182). Knowledge 
was positively correlated with education (rho=0.238, p<0.001) and negatively correlated with 
age at diagnosis (rho=-0.224, p<0.001) and current age of participants (rho=-0.206, p<0.05). Age 
was negatively correlated with education (rho=-0.189, p<0.05).  
2.3.5 Management of diabetes  
Sixty-one percent of patients were taking oral anti-diabetic drugs (OADs), 33% were on insulin, 
3% were on both OAD and insulin, and 3% were not taking any glucose-lowering medication. 
The distribution of participants using one OAD or more, and/or insulin is shown in Table 4, p.24. 
Insulin usage was higher among male compared to female participants (Χ²=4.195, p=0.041).  
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Table 4 Medical therapy of diabetic patients 
Type of medication [%] Overall  
(n=155) 
Female  
(n=82) 
Male  
(n=73) 
No oral anti-diabetic drug  3.9 3.6 4.1 
One oral anti-diabetic drug  20.6 25.6 15.1 
Two oral anti-diabetic drugs  39.4 41.5 37.0 
Three oral anti-diabetic drugs  0.6 1.2 0 
Insulin  32.9 25.6 41.1 
Insulin + oral anti-diabetic drug  2.6 2.4 2.7 
 
Fifty-one percent were members of the National Health Insurance Fund (NHIF). Patients who 
were teachers or retired had better coverage than other occupational groups, with 91% and 
71% being insured, respectively. The share of non-insured patients was greater among the 
business sector, artisans, housewives, and students. Among the remaining professions, 
approximately 50% were members of NHIF. Medication was either paid for by the insurance 
system, through donations (5%), or by patients if no insurance was available. Median weekly 
costs were 12,000 TSH and tended to be higher for insulin (15,000 TSH) compared to OAD 
(10,000 TSH). No information was collected on the availability of medications and medical 
adherence. At the time of the survey, a regular checkup and consultation with a doctor cost 
1000 TSH and was covered by insurance, donation, or the patient. The plurality (47%) of the 
patients went for checkup twice a year (Table 5). The frequency of regular checkups at the 
clinics did not differ between insured and non-insured participants or females and males.  
Table 5 Checkup frequency of diabetic patients 
Frequency [%] 
 
Overall  
(n=155) 
Twice a week 0.6 
Weekly 6.5 
Monthly 34.2 
Every two months 2.6 
3-5 times per year 50.3 
Twice per year 2.6 
Once per year 3.2 
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Almost 70% felt that their diabetes was well controlled, 9% felt that their diabetes was not well 
controlled, and 22% did not know. Eighteen percent of the patients were members of a diabetes 
support group. Patients were asked whether they thought that eating and physical activity 
habits influenced blood glucose levels. An affirmative answer was given by 87% and 88% of 
patients, respectively, and 97% and 89% said they had changed their habits. The majority (75%) 
stated they had reduced carbohydrate and sugar intake and increased vegetable intake (52%) as 
well as reduced fat and fried food (14%). In regard to physical activity, patients said they 
included walking (62%), running (15%), more farm work (18%), and more household chores 
(18%) into their physical activities.  
2.4 Discussion 
2.4.1 Associations between diabetes with demographics and anthropometrics  
This study included 155 adult patients with a median age of 57 years, comparable to age 
distributions in other diabetes studies conducted in Tanzania (Brown et al. 2014; Chiwanga et al. 
2015; Rwegerera 2014). These results are consistent with estimations by the IDF, in which 50% 
of all diabetic cases fall into the age range of 40 to 59 years (IDF 2013). In the current study, 
farmers were significantly older than non-farmers at diagnosis, with no difference in BMI. This 
difference may be due to higher physical activity among farmers and, thus, delayed onset of 
diabetes. Physical inactivity is one factor that can influence the development of diabetes type 2 
(Manson et al. 1991; Sigal et al. 2006). Information on physical activity in Sub-Saharan African 
countries is limited (Mbanya et al. 2010). The current findings suggest physical activity may be 
important in delaying the onset of diabetes. As rates of sedentary work increase, physical 
activity outside of work should be explored.  
 In Tanzania, the national ratio of men to women is 49% to 50% (National Bureau of 
Statistics, Ministry of Finance, et al. 2013; National Bureau of Statistics & Ministry of Finance 
2013), which is similar to the  ratio of 47% to 53% in the current study. According to the IDF, 
there is no significant difference between sexes, although more men are expected to have 
diabetes by 2035 (IDF 2013). In the current study, more participants were married or widowed 
than in the Tanzanian Demographic Health survey; this can be attributed to the higher median 
age in the current study than in the overall population (National Bureau of Statistics et al. 2011). 
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The median household size of 5 in the current study is similar to the median of 4.9 in the 
Mainland of Tanzania (National Bureau of Statistics et al. 2011).  
 Fifty-one percent of the diabetic patients were members of the National Health 
Insurance Fund (NHIF). This fund was established in 1999 and aims to include all formal sector 
employees. The Kilimanjaro Region has an enrollment rate of 8%. Benefits of NHIF include 
registration and consultation, and the payment of medical costs, investigations fees, and 
impatient care services, among others (Ministry of Health and Social Welfare 2007; National 
Health Insurance Fund 2013).   
 Overweight and obesity are among the modifiable risk factors that contribute to the 
development of type 2 diabetes mellitus. Several Sub-Saharan African studies have found 
associations between overweight and obesity and diabetes (Mbanya et al. 2010; Mclarty et al. 
1989; Aspray et al. 2000; Amoah et al. 2002; Motala et al. 2008). In many low- and middle-
income countries, people associate overweight or obesity with a healthy and affluent lifestyle, 
and not with impaired health and increased risk factors for diseases (Sircar et al. 2010; McLaren 
2007). Female participants in the current study had significantly higher BMI values and higher 
percentage of obesity than male participants. These sex discrepancies were also seen in other 
Tanzanian study settings (Kavishe et al. 2015; Njelekela et al. 2009). A study in urban Tanzania 
found a higher risk for signs of metabolic syndrome among obese women (Njelekela et al. 
2009). Although females tended to be younger at diagnosis, having a higher BMI than males, 
BMI was also positively correlated with age at diagnosis in the overall study population. A 
combination of increased BMI and age might be a risk factor among the current study 
population, regardless of sex. However, this relationship needs further investigation with a 
larger sample size. Although mean BMI was similar to a study conducted at KCMC in 1999 
(Hoffmeister et al. 2005), obesity rates among women were more than double in the current 
study (8% vs. 17%). Unlike the 1999 study (Hoffmeister et al. 2005), the current study also 
included type I diabetic patients, which usually do not have body weight in overweight or obese 
ranges. Thus, rates of overweight and obesity among type 2 diabetic patients alone may have 
been even higher. However, as no data on the type of diabetes was collected from the medical 
charts, no separate calculation was performed. Data from the founding years of the diabetes 
clinic at KCMC showed obesity prevalence of 15% among type 2 diabetic patients (Neuhann et 
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al. 2002). A study at the Muhimbili National Hospital in Dar es Salaam showed rates of 40% and 
32% overweight and obesity among type 2 diabetes patients, respectively (Rwegerera 2014). In 
Tanzania, overweight and obesity rates are higher among women and urban residents 
compared to men and rural residents (Kavishe et al. 2015; Njelekela et al. 2009), although rates 
are increasing in rural areas as well (Keding et al. 2013). In urban areas, 36% are considered 
overweight or obese. No data on the nutritional status of men is presented in the Tanzania 
Demographic Health Survey from 2010 (National Bureau of Statistics et al. 2011).  
 Body weight gain of diabetic patients can also occur due to side effects of OAD, 
especially of sulfonylureas (Mitri et al. 2009) . A study follow-up assessment has shown that 
patients with sulfonylureas treatment increase their body weight by 5 kg over a mean duration 
of 6 years after starting with the medication (UKPDS 1998). Table 6, p. 31 indicates what types 
of OAD are associated with body weight gain. Insulin therapy is often associated with weight 
gain, mainly in the first months after starting the drug regimen (Mitri et al. 2009; Yki-Järvinen et 
al. 2012). Approaches to manage body weight gain due to medical therapy in diabetic patients 
include the use of weight loss drugs such as orlistat (Berne et al. 2005) and others (Hollander 
2007). However, weight loss or stabilization of body weight with the help of lifestyle 
adjustments in addition to the intake of hypoglycemic agents may be appropriate and cost-
effective to reach targeted glycemic control instead of adding addition medications to control 
for weight gain (Mitri et al. 2009).  
2.4.2 Low knowledge and usage of bitter gourd  
Only 7% of diabetic patients knew bitter gourd. This may be due to the fact that bitter gourd is 
mainly collected from the wild and used in the Asian cuisine in East Africa (Njoroge et al. 1994). 
At the time of the study, bitter gourd was available from one vendor at the local center market 
or from private people who grew bitter gourd in their garden. By the end of 2011, bitter gourd 
(Figure 5, p. 28) was also available at the newly established Kenyan supermarket chain 
Nakumatt in Moshi  (Rawlings 2011). However, the commonly reported consumption of bitter 
tasting vegetables among interviewees and the use of phytomedicine show that there is a 
positive attitude towards medicinal plants and their usage.     
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Figure 5 Bitter gourd fruits sold at the local center market in Moshi 
 
2.4.3 Health-related and economic burden  
Approximately half of the participants had first- or second-degree relatives who were diabetic. 
Similar and even higher rates were also found elsewhere (Guler et al. 2011). A study among 
participants with gestational diabetes reported that, in the urban area, 14% had a family history 
of diabetes (Mwanri et al. 2014). This underlines that a family history of diabetes is a risk factor 
for the disease. Having more than one family member suffering from diabetes may increase 
financial burden on the family with regard to medical care.  
 Only one participant reported developing diabetes during pregnancy. In a study 
conducted in Dar es Salaam and Kilombero District, 5.9% of pregnant participants were 
diagnosed with gestational diabetes with a significant difference between urban (8.4%) and 
rural (1.0%) settings (Mwanri et al. 2014). Longitudinal studies are needed to assess the extent 
of the progression of gestational diabetes to type 2 diabetes mellitus.  
 The median duration of 8 years since diagnosis of diabetes was comparable to findings in 
other studies (Sircar et al. 2010; Al-Qazaz et al. 2011; Sweileh et al. 2014). The complication 
most mentioned by patients in the current study was related to retinopathy with impaired sight 
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and blindness. Retinopathy is one of the most common microvascular complications among 
diabetic patients (Fowler 2008) and might by related to the severity of hyperglycemia and the 
presence of hypertension (Group UKPDS 1998). Almost half of the patients reported having 
hypertension. Hypertension is a common comorbidity among diabetic patients, with rates 
ranging from 20 to 60%, and may require additional medical therapy to prevent complications 
(ADA 2003).  
 A study conducted in Dar es Salaam found a 15.3% prevalence of diabetic foot ulcers 
(Chiwanga et al. 2015). Foot ulcers are a major risk factor for future amputations (Boulton et al. 
2005). In the current study, amputations were reported by 1.3% of patients. Although the 
current study was not representative, more diabetic patients of KCMC and MLH may have had 
amputations. In a resource-poor setting like the current study, patients with amputations may 
face greater difficulties in traveling to diabetes clinics. To avoid a progression of foot ulcers to 
amputations, regular foot care can include examinations by a doctor and self care by patients.  
In the study in Dar es Salaam, only 27.5% of patients said they had a foot examination by a 
doctor since diagnosis, and many patients did not perform foot self care (Chiwanga et al. 2015).  
 In the current study, the long delay between patients' initial perceptions of symptoms 
and diagnoses may have been due to an unfamiliarity with the symptoms of diabetes. A 
qualitative study showed that symptoms of diabetes mellitus, e.g., frequent urination and 
itching around the genital area, have been mistaken by health professionals for signs of urinary 
tract infections and sexually transmitted diseases. Further, it was reported that diabetes 
symptoms were mistaken for signs of malaria and HIV. In the case of HIV, patients were 
reluctant to seek medical care for fear of stigmatization. The study concluded that knowledge 
about diabetes was scarce among the public and among health professionals, and that patients 
acquired knowledge after diagnosis (Metta et al. 2015). This may be the case for the current 
setting as well, where posters on diabetes symptoms, complications, and foot care were 
displayed in the examination rooms and consultation office. Lack of awareness of diabetic 
glucose levels has been reported for Tanzania (Kavishe et al. 2015).   
 Approximately 17% of the participants reported having given up something to pay for 
diabetes management. Most of them were not members of NHIF. The financial burden and 
occasional dependence of diabetic patients on other family members as caregivers or financial 
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supporters, were mentioned by diabetic patients in a similar setting (Kolling et al. 2010). 
Checkup prices reduced from an initial cost of 8,000 TSH in the founding years of the diabetes 
clinic at KCMC (Neuhann et al. 2002) to 1,000 TSH.  
2.4.4 Knowledge on diabetes – achievements and challenges  
In the current study, 75% of participants did not know what type of diabetes they had. 
However, according to the ADA, it is more important to understand the pathogenesis of 
hyperglycemia and effective treatment (ADA 2010). Among patients, symptoms were more 
commonly known than causes or complications. However, this knowledge was probably gained 
after diagnosis. This assumption is similar to findings by Metta et al. who conclude that 
awareness and knowledge about diabetes signs and symptoms was limited, especially prior to 
diagnosis (Metta et al. 2015). Knowledge was positively correlated with education and being a 
non-farmer. Educational level was significantly higher among non-farmers than farmers. Other 
studies also found an association between education and knowledge (Chiwanga et al. 2015; 
Guler et al. 2011) as well as between education and the likeliness of medical adherence 
(Sweileh et al. 2014), whereas others did not detect a relationship between education and 
knowledge on and practices in diabetes (Sircar et al. 2010). As education was negatively 
correlated with age, knowledge was also negatively correlated with current age and age at 
diagnosis. This was also seen elsewhere (Guler et al. 2011).  
2.4.5 Problems in the management of diabetes 
Almost all patients in the current study were taking some form of medication for blood glucose 
control, either OAD, insulin, or both. Patients using only OAD take a combination of metformin 
and sulfonylurea tablets (38%), only sulfonylurea tablets (14%), or only metformin tablets (9%). 
Patients were not asked about knowledge of the different kinds of medications used and their 
modes of action. An understanding of hyperglycemia and its treatment possibilities is important 
for a successful treatment (ADA 2010), so future studies should assess patient knowledge of 
medications used and the underlying pathogenesis of hyperglycemia that is treated. Table 6, p. 
31, shows an overview and hypoglycemic medications.  
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Table 6 Overview on oral anti-diabetic drugs (Biesalksi, HK et al. 2010) 
Active ingredient 
Can cause 
hypoglycemia (in 
monotherapy) 
Increases 
insulin 
secretion 
Weight 
gain 
Sulfonylureas    
Glibenclamide yes yes yes 
Gliclazide yes yes yes 
Glimepirid yes yes yes 
Gliquidon yes yes yes 
Glinides    
Repaglinide yes yes yes 
Nateglinide yes yes yes 
Biguanides    
Metformin no no no 
Dipeptidyl Peptidase-IV 
Inhibitors 
   
Sitagliptin no yes no 
Vildagliptin no yes no 
Saxagliptin no yes no 
Thiazolidinedione    
Pioglitazone no no yes 
Rosiglitazone  no no  
α-glucosidase Inhibitors    
Acarbose no no no 
Miglitol no no no 
 
The intake of more than one OAD was also reported in other studies (Chiwanga et al. 2015). The 
current study did not assess medical adherence or availability of medical care. A recent review 
identified several factors that influence medical adherence in patients who take multiple 
medications. These include social and economic factors, medication-therapy-related factors, 
patient-related factors, and health-care-provider and health-system-related factors (Marzec et 
al. 2013). During conversations with current study participants, they mentioned difficulties in 
obtaining a constant medical supply, especially in the case of insulin. A similar observation was 
made in a study among urban poor diabetics in Dar es Salaam. There, a patient described 
attempts to obtain insulin as very challenging and expensive. In case of the unavailability of 
OAD, patients may seek treatment from traditional healers (Kolling et al. 2010). A comparison 
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(Robertson et al. 2015) of three different assessments (Peck et al. 2014b; Ministry of Health and 
Social Welfare, Tanzania 2013; WHO/HAI 2008) of medicine availability in Tanzania revealed a 
shortage of medications for diabetes and hypertension in both governmental and private 
facilities. Availability of metformin and glibenclamide ranged from 33-57% and 19-59%, 
respectively. Availability of medicine was influenced by the managing authority, facility level, 
and setting. The authors concluded that availability was higher in mission-owned and privately 
owned institutions than in government facilities, was higher in hospitals than in health centers 
and dispensaries, and higher in urban than in rural settings. Reasons for suboptimal availability 
were not explored. Another study reported that medicines for diabetic patients in Dar es Salaam 
are available in private pharmacies (84%) and hospital pharmacies (16%) (Brown et al. 2014).  
 Approximately 50% of current patients had to pay for their medication and glucose 
control, which can also influence medical adherence. A study among patients at Muhimbili 
National Hospital in Dar es Salaam reported adherence rates of 60% and 71% during the 
previous week and three months, respectively. Adherence was associated with concurrent use 
of other medications and was found to be good among elderly patients. Poor adherence was 
linked to costs and side effects (Rwegerera 2014). Another study among diabetic patients in 
Palestine revealed an even lower adherence of 57%. Knowledge about diabetes was associated 
with adherence. Patients with higher diabetes knowledge scores were less likely to be 
nonadherent. Seventeen percent stopped taking their medication after they felt their diabetes 
symptoms were controlled (Sweileh et al. 2014). Medical adherence is important for glycemic 
control. A study in Malaysia revealed that monotherapy, higher diabetes knowledge, and higher 
medical adherence were associated with glycemic control (Al-Qazaz et al. 2011).  
 The current study did not assess medical data on glycemic control. Regular 
measurements of HbA1c were reported to be lacking among participants. A study conducted at 
KCMC in 2006 showed that 65% of diabetic patients (type 1 and type 2) had HbA1c levels >8.5% 
(Michaelsen, Jens Kersten 2011). The availability of measurements of long-term glucose 
parameters should be evaluated to improve glucose control among patients. In contrast to high-
income countries, Tanzania has few diabetic patients who own a glucometer for self monitoring 
of glucose levels (Smide et al. 2002). The presence of only three clinical staff members poses a 
major challenge to providing adequate care to diabetic patients. Such a lack of human resources 
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was also demonstrated in other Tanzanian settings (Peck et al. 2014b). Availability of equipment 
for diabetes diagnosis and management needs to be improved, despite efforts to do so during 
the past decade.  
 Most of the patients stated to have changed their dietary intake patterns and physical 
activity patterns after the diagnosis. Most reported changes were increased intake of vegetables 
and an increase in physical activity. In regard to physical activity, diabetic patients should 
engage in at least 150 min per week of moderate aerobic physical activity on at least three days 
per week with no more than two days without physical activity (ADA 2016). Recommendations 
for medical nutrition therapy among type 2 diabetic patients with no renal impairment include 
intake of carbohydrates from whole grains, fruits, and vegetables, protein (15-20% of overall 
energy intake), saturated fat <10% of total energy intake, one alcoholic beverage for women 
and two for men, among other (Franz et al. 2002). More detailed recommendations are given in 
the appendix (D).  
2.4.6 Limitations 
The current study had several limitations. Due to the small sample size, results cannot be 
generalized. Patients were recruited by convenience sampling and interviewed on the first 
upper level of a building, which may have prevented participation of patients with advanced 
complications such as amputation and blindness. No data were collected with regard to 
glycemic control, medical adherence, or treatment availability. However, the current study 
collected data to explore existing problems among diabetic patients in the Kilimanjaro Region. 
The findings of the study were similar to those of other studies. Thus, ideas for future 
intervention programs and research questions could be derived.   
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2.4.7 Conclusion and outlook 
The current survey showed that diabetes knowledge was present among patients, although it 
was presumably acquired after diagnosis. In addition, diabetes care imposed extra burdens on 
some participants. The existence of complications shows the need to improve diabetes 
management, including possibilities to monitor long-term glucose levels. Overall, there is a need 
to further educate patients about diabetic complications and further expand research on 
lifestyle changes after diagnosis. 
Suggested interventions for the Kilimanjaro Region 
 Education about diabetes signs and symptoms and risk factors at public and private 
places, such as workplaces, churches, mosques, schools, supermarkets, and news media 
 Increase in health staff for diabetes care 
 Establishment of equipment for long-term glucose control 
 Establishment of equipment for detection of diabetes-related complications 
 Establishment of local diabetes support groups 
 Education about lifestyle changes among diabetic patients 
 Systematic monitoring of medicine availability at health facilities 
 Exploration of possibilities to increase access to medical insurance 
Suggested follow-up research topics  
 Medical adherence and possible barriers  
 Medical adherence and glycemic outcomes during religious fasting 
 Food intake and physical activity among diabetic patients 
 Use of traditional medicine among diabetic patients  
 Knowledge about diabetes among communities  
 Potential means to spread and increase knowledge about diabetes  
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Chapter 3: Anti-diabetic effects of bitter gourd consumption for two months among 
pre-diabetics in Moshi, Tanzania  
3.1 Objectives 
The major objective of the recruitment procedure was to recruit subjects for the dietary 
intervention study in Moshi, Tanzania. Further, this dissertation aimed to elucidate the process 
and approach of the recruitment procedure, health aspects of the participants, and enrollment 
rate.  
 The major objective of the intervention study was to assess anti-diabetic effects of daily 
bitter gourd consumption of 2.5 g powder over the course of eight weeks among pre-diabetic 
persons. The primary endpoint was FPG measured at endline with an expected difference in 
between bitter gourd and placebo group. Secondary endpoints were HbA1c, insulin, high-density 
lipoprotein (HDL), cholesterol (Chol), triglycerides (TG), BP, and BMI. 
3.2 Method section 
3.2.1 Study area and subjects 
The study was conducted at the Kilimanjaro Clinical Research Institute (KCRI) located in Moshi 
Municipality (Figure 6, p. 36) in the Kilimanjaro Region, Tanzania. The Kilimanjaro Region is 
located in northern Tanzania and had a population of 1,640,087 in 2012 (National Bureau of 
Statistics & Ministry of Finance 2013). Participants were recruited during a two-stage screening 
procedure.  
 The inclusion criteria for eligible participants were: pre-diabetes diagnosis based on the 
ADA's FPG cut-off values of 5.6-6.9 mmol/L (100-125 mg/dL) (with IFG on two days or IFG on 
one day in addition to eligible HbA1c), HbA1c of 5.7-7.5% (39-58% mmol/mol), BMI of 27-35 
kg/m², BP of 90/60-160/110 mmHg, age between 30-65 years, and waist circumference (WC) 
>80 cm for women and >90 cm for men. Exclusion criteria were: having any clinically diagnosed 
disease, taking medication regularly, having an identified glucose-6-phosphatase-
dehydrogenase (G6PD) deficiency, heavy alcohol consumption, pregnancy, and breastfeeding. 
The study-related HbA1c upper limit exceeded ADA recommended cut-off points for pre-
diabetes. During the screening process, HbA1c levels were found to be high, whereas the FPG 
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levels of the same participants were moderate. The use of a higher cut-off in the HbA1c criterion 
was approved by the Institutional Review Boards of National Institute for Medical Research 
(NIMR) and Kilimanjaro Christian Medical College. During 2013/2014, HbA1c cartridges were 
recalibrated by HemoCue®, which resulted in lower readings compared to old cartridges. 
However, a correction factor was not provided by the manufacturer, and was instead calculated 
by comparing old and new cartridges analyzed by the HemoCue® 501 analyzer 
(HemoCue®GmbH, Germany) and another HbA1c point-of-care analyzer (DCA Vantage Analyzer, 
Siemens, Germany). Corrected HbA1c levels are presented in the current analysis. During the 
screening process, eligibility criteria were based on uncorrected HbA1c values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Location of the study area in Tanzania (Destination360 2006)  
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3.2.2 Study design and randomization 
The current study was a randomized, single-blind, placebo-controlled, cross-over designed 
intervention study (Figure 7, p. 38). This superiority study was divided into an AB-BA sequence. 
“Group 1” (AB) started with bitter gourd supplementation, followed by placebo. A washout 
period of four weeks was conducted between the two supplementation periods. “Group 2” (BA) 
started with placebo followed by bitter gourd supplementation with a four-week washout 
period in between. A four-week washout period has been shown previously to prevent carry-
over effects (Tsai et al. 2012).  
 After completion of the screening, all identification codes of eligible participants were 
entered into SPSS. As the screening did not result in a number of participants exceeding the 
calculated sample size, all eligible participants were included into the randomization process 
and placed into sequence groups. Randomization was performed using the Mersenne Twister 
random number generator (Matsumoto et al. 1998). To ensure equal distributions of female 
and male participants, both sexes were separately randomized to each group.  
 Participants were blinded to the group assignment, provided with sachets containing 
either bitter gourd powder or placebo (cucumber), and instructed to mix the powder with 150 
mL of provided drinking water and consume it after a main meal (appendix J). Because almost 
no previous studies were conducted on bitter gourd use by pre-diabetics, the research 
coordinators were not blinded to the group assignment, so they could intervene in case of any 
hypoglycemic event caused by bitter gourd supplementation. All participants were instructed 
not to change their eating habits or physical activities during the intervention study. Compliance 
with instructions was assessed in weekly regular checkup questionnaires. In addition, 
participants received a calendar and stickers to mark their consumption of sachet contents and 
presented the calendar at each visit.   
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Figure 7 Design and assessment time points of the intervention study 
 
3.2.3 Sample size 
Sample size was calculated using G*Power 3.1 (Faul et al. 2007). The calculation was based on 
an expected difference of 0.56 mmol/L (10 mg/dL) in mean FPG between groups, a standard 
deviation of 0.94 mmol/L (17mg/dL) in each group, an alpha level of 0.05 and a power of 0.95 
and was equal to 63 participants. However, this was based on a paired t-test. A period effect 
was observed after the completion of the study, making the comparison of matched pairs 
inappropriate. Thus, the sample size was recalculated based on a two-sample t-test, with a 
standard deviation of 0.56 mmol/l (10mg/dl) in each group, and with the same expected 
difference, alpha level, and power. The recalculated sample size was 54 participants.   
3.2.4  Preparation of sachets and dosage  
The bitter gourd variety used in the study was NS1020 from Namdhari Seeds Pvt. Ltd® (India) 
and was grown and harvested at the AVRDC in Taiwan between July and September 2012. The 
cucumber variety used was MALANITM from Seminis® (India), also grown at AVRDC. Bitter gourd 
and cucumber fruits were washed with clean water and dipped into water containing 1-2% 
hydrogen peroxide. Fruits, including seeds and skin, were chopped, freeze-dried, and ground 
Baseline_1 Baseline_2 Endline_1 Endline_2 
Methods 
40 
 
into powder (80 mesh). Processing was performed by Challenge Bioproducts Co., Ltd. (Taiwan). 
Mixing of powders with additives and packing was performed by TAI WON FOOD INDUSTRIAL 
CO., Lt TDTaiwan). Both were certified according to ISO 22000 and HACCP. The daily dosage of 
bitter gourd was 2.5 g, based on results of a previous animal trial in which the equivalent dosage 
of 500 mg/kg body weight improved insulin sensitivity in high-fat-diet mice. In the same trial, 
raw bitter gourd was more effective than cooked bitter gourd (unpublished data). A daily 
dosage up to 4.8 g has been found to be safe for humans (Tsai et al. 2012). To mask the bitter 
taste, 0.75 g alpha-cyclodextrin mixed with 2% lemon peel oil (CAS Number 8008-56-8), 75 mg 
beta-cyclodextrin, 15 mg steviol glyscoside, and 0.75 g cucumber powder were added to the 
bitter gourd powder. The placebo contained 3.25 g of raw cucumber powder in addition to the 
aforementioned ingredients (except additional cucumber powder). Alpha-cyclodextrin was 
purchased from SEI CHENG CHEMICAL CO., LTD. Company (Taiwan), beta-cyclodextrin was 
purchased from Baolingbao Biology Co., Ltd (China), and steviol glycoside was purchased from 
YIH YUAN FOOD ADDITIVES & CHEMICAL INDUSTRIAL CO., LTD. (Taiwan). All concentrations 
were in accordance with regulations of the Food and Drug Administration (Nutrition Center for 
Food Safety and Applied 2004; Nutrition Center for Food Safety and Applied 2001) and of the 
European Union (European Commission 2011). Sachets were shipped to Tanzania after 
obtaining permission from the Tanzanian Food and Drug Authority (TFDA) and stored in a 
cooling room until distribution. Participants received sachets and drinking water on a weekly 
basis during their regular checkup appointments. A closable cup, with a marking at 150 ml, was 
provided to mix the powder and water.  
3.2.5 Recruitment procedure – two-stage screening approach  
The recruitment procedure for pre-diabetic participants was conducted in Moshi Urban District, 
one of the six districts of the Kilimanjaro Region in northern Tanzania. The Kilimanjaro Region 
had a population of 1,640,087 in 2012 (National Bureau of Statistics & Ministry of Finance 
2013). Moshi Municipality, the capital of Moshi Urban District, is divided into 21 wards (Moshi 
Municipality Council 2012) of which seven (Longuo, Rau, Karanga, Mawenzi, Majengo, Mji 
Mpya, Njoro, Pasua) were chosen as pre-screening areas (Figure 8, p. 40). They were chosen due 
to their proximity to the screening facility in Longuo or due to their use in previous studies 
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(Ludwig et al. 2013). Screening took place at the KCRI, which is the third pillar of the Good 
Samaritan Foundation and is closely associated with the KCMC (Manta Ray Media 2015).  
 
Figure 8 Selected wards (highlighted in grey) for the recruitment procedure in Moshi adapted 
from (Moshi Municipality Council 2012)  
 
The recruitment procedure was divided into two phases. Between April and October 2013, a 
pre-screening phase informed institutions and congregations of the upcoming research study. 
When possible, people were screened for eligible BMI and age during this phase. The pre-
screening took place at 16 different settings in Moshi and included the following gatherings or 
institutions: single people from Njoro and Pasua identified as pre-diabetics in a previous study, 
clinical conference for doctors and nurses at KCMC, radio announcement, three Lutheran 
churches, four Catholic churches, one convent, two banks, teachers at two primary schools, staff 
and lecturers at one university, one mosque, one police academy, one revenue authority, and 
KCRI. Before any data was collected, information was provided about the rationale, aims, 
procedures, and target group. After the information session, people had the opportunity to ask 
questions and to stay for a subsequent data assessment. The type of data assessment differed 
between pre-screening sites in regard to contact information, age, BMI, and BP. The latter was 
not yet matched to inclusion criteria. In the early stages of the pre-screening, body weight was 
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measured with an analogue scale and height with an elastic measurement tape fixed to a 
straight wall. In the later stages, body weight was measured with a digital scale (Seca 877 
Germany) and portable stadiometer (Seca 217, Germany). Body mass index was calculated as 
bodyweight in kg divided by the square of body height in m. While seated, each participant's BP 
was measured on the left arm using a Visomat Double Comfort BP cuff (range: systolic 50-250 
mmHg, diastolic 40-150 mmHg, Uebe Medical GmbH, Germany). All measurements were 
performed once. Body mass index and BP values were categorized according to WHO guidelines 
(WHO 1999, WHO 2015) and American Heart Association (AHA 2015) guidelines, respectively. 
All participants with eligible BMI and age were invited to the screening for pre-diabetes. Every 
eligible participant was called and instructed to fast overnight prior to a scheduled 
appointment.  
 The screening for pre-diabetes and all other eligibility criteria took place at the KCRI 
between July and October 2013. Pre-screening and screening activities at KCRI were performed 
simultaneously. Screening appointments were scheduled between 7:30 and 10:30 a.m. An 
assessment of body weight and height, a questionnaire-based interview, and a BP measurement 
were performed in assessment room one. Fasting plasma glucose and HbA1c were measured in 
assessment room two. The screening time was about five minutes in each room. Body weight 
was measured using a digital scale (Seca 877, Germany). Body height was measured using a 
portable stadiometer (Seca 217, Germany) according to FANTA protocol (Cogill 2003), with 
participants dressed in light clothing and without shoes. Measurements were performed only 
once. Waist circumference and hip circumference (data not shown) were measured twice using 
a retractable measurement band according to STEPS Surveillance (WHO STEPS Surveillance 
2008). If the difference between the two measurements was greater than 1 cm, a third 
measurement was performed. The mean of the measurements was then recorded. Afterward, 
the participant was asked to sit for an interview. A standardized screening questionnaire was 
used to assess socioeconomic and health-related data (appendix E, F). After five minutes, BP 
was measured once with the participant seated.  
 In assessment room two, capillary blood samples were obtained from a dry, disinfected 
fingertip using one-way lancets. Fasting plasma glucose was measured using Accuchek Aviva®  
(Roche Diagnostics, Switzerland). Glycosylated hemoglobin was measured with HemoCue® 501 
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analyzer, (HemoCue® GmbH, Germany). Both appliances are point-of-care devices and results 
were available after a few seconds for FPG and after five minutes for HbA1c. Participants with 
unknown diabetic glucose levels or diabetics with high glucose levels were advised to go to their 
nearest clinic for further medical consultation. During a run-in period, G6PD deficiency was 
assessed using CareStartTM G6PD (Access Bio, USA), a rapid test kit for capillary blood. All 
participants were reimbursed for their traveling and given a chart of their data, reference 
ranges, and a small snack. If requested, participants were given counseling for nutrition and 
physical activity as part of a healthy lifestyle.  
3.2.6 Data collection  
All data were collected and documented into patients’ files during the intervention study and 
into case report forms. Further, each participant received his or her measure values on a 
separate form.  
Demographics, anthropometrics and blood pressure  
Socioeconomic, demographic, and medical data were obtained using a standardized 
questionnaire at the baseline assessment before the start of the intervention study. Data were 
obtained about marital status, educational status, profession, and medical history. 
Questionnaires were compiled in English and then forward and backward translated to check 
for inconsistencies. Interviews were conducted in Swahili, the local national language.  
 Anthropometric measurements were conducted with the same devices as used during 
the screening. Body weight was measured to the nearest 0.1 kg using a digital scale (Seca 877, 
Germany). Body height was measured to the nearest 0.5 cm using a portable stadiometer (Seca 
217, Germany). Measurements were performed once. Body mass index was calculated as stated 
before weight. Waist circumference and hip circumference (data not shown) were measured 
twice using a retractable measurement band. If the difference between the two measurements 
was greater than 1 cm, a third measurement was performed. The mean of the measurements 
was then recorded.  
 After a five minute rest period in a seated position, each participant's BP was measured 
using a digital blood pressure monitor on the left arm (Visomat Double Comfort, Uebe Medical 
Methods 
44 
 
GmbH, Germany). Body weight and BP were assessed before and after each supplementation 
phase and at every weekly visit of the participants.  
Blood samples 
Before and after each supplementation period, a 5 ml venous blood sample was drawn from 
participants by a certified nurse. Participants were instructed to arrive after at least eight hours 
of fasting and were rescheduled if they had not fasted. From the venous blood samples, 
concentrations of FPG, HDL, TG, Chol, insulin, glutamate pyruvate transaminase (GPT), and 
creatinine were analyzed. The latter two were assessed as parameters for liver and kidney 
function. Fasting plasma glucose, HDL, TG, Chol, GPT, and creatinine were analyzed using 
ReflotronPlus®, Roche Germany. Reagents were purchased by Roche Germany. Insulin was 
analyzed via the ELISA technique using a BioTek® Human Insulin (INS) ELISA Kit manufactured by 
Bioassay Technology Laboratory, Shanghai, China.   
 Capillary blood samples were obtained from a dry, disinfected fingertip to assess 
capillary FPG and HbA1c. Fasting plasma glucose was assessed using Accu-Chek Aviva® (Roche 
Diagnostics, Switzerland). Glycosylated hemoglobin was measured using HemoCue® 501 
analyzer (HemoCue® GmbH, Germany). Results were ready after a few seconds for FPG and after 
five minutes for HbA1c. Capillary blood samples were obtained before and after each 
supplementation period, and also during weekly visits of participants. The weekly 
measurements are not shown here. After each assessment appointment, participants were 
provided with a small snack.  
Food intake and physical activity  
To assess changes in food intake and physical activity, a qualitative food frequency 
questionnaire (FFQ) (appendix H) and physical activity questionnaire (PAQ) (appendix I) were 
conducted. Participants were interviewed during the run-in period (one week before the start of 
the intervention) and at the end of the intervention. The FFQ covered the previous month. To 
compare food intake data, a monthly food variety score was calculated. In regard to changes in 
physical activity, only the sports section of the PAQ was compared. Both questionnaires were 
pre-tested in a study in 2012 in the same study area and adjusted afterward to cover locally 
available and consumed foods. Additionally, the weekly regular checkup questionnaire included 
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questionsonwhethertheparticipantchangedhisorherfoodintakeandphysicalactivityduring
thepreviousweekand,ifyes,whatkindsofchangesweremade.
Adverseeventsandsideeffects
Adverseeventsandsideeffectsreportedbyparticipantswererecordedontheregularcheckup
questionnaire(appendixG)duringeachweeklyvisit.Thisquestionnairealsoincludedtheuseof
medicationduringthepreviousweek.Inaddition,GPTandcreatininevalueswerecheckedafter
everyassessmentforclinicallyelevatedvalues.
3.3 Statisticalanalyses
Statisticalanalysesoftherecruitmentprocedure
DataentryandanalysiswereperformedusingMicrosoftExcel2013,SPSSversion22(SPSSInc,
ChicagoIllinois),andStataversion14.Variablesareexpressedasfrequenciesorasmedianand
interquartilerange.OnlyWCwasconsistentwithanormaldistributionanddescribedbyamean
andstandarddeviation.AMannWhitneyUtestwasusedtoidentifydifferencesincontinuous
variables between male and female participants. A Chisquared test was used to identify
differences between categories in categorical variables. Among the prescreening sample,
Spearman's rho was calculated to assess correlations. Concordance between FPG and HbA1c
measurements of dysglycemiawas calculated using Krippendorff’s alpha (Hayes et al. 2007).
DysglycemiawasdefinedbyFPG5.6mmol/L (100mg/dL)orHbA1c5.7%(39mmol/mol).
Concordanceof theglycemicstatus (normal,prediabetic,ordiabetic)willbepresentedusing
cross tabulation. Among the screening sample, a nonlinearmodel with seemingly unrelated
regression(SUR)(Wooldridge2010)wascomputedtoanalyzeeffectsofageonFPG,HbA1c,and
BP,aswellastoanalyzeeffectsofWCandBMIonthedependentvariables.Agewascontrolled
forgender;WCandBMIwerecontrolledforageandgender.Ifnecessary,thequadricvariation
ofthecenteredindependentvariablewasused.Fastingplasmaglucose,HbA1c,andBPwerelog
transformedprior to analyses. For theseparticularmodels, participantswho takemedication
regularlyorwerepregnantwereexcluded.Resultswereconsideredstatistically significant for
p<0.05.

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Statisticalanalysesofinterventionstudy
Double data entry and checking were performed using SPSS version 21 (SPSS Inc, Chicago
Illinois). Data were analyzed using SPSS version 22 (SPSS Inc, Chicago Illinois) andMicrosoft
Excel2013.DescriptivedataarereportedasmeanandSD.Perprotocol,analysiswasperformed
for data from venous blood samples, anthropometrics, and BP. Other variables, such as
socioeconomicdata,wereanalyzedforall52participantswhofinishedthestudyinMarch2014
but had missing bloodsample data. As no capillary FPG levels were hypoglycemic and no
participantshowedsignsofhypoglycemia,venousFPGvalues<3.3mmol/Lwereexcluded.For
other variables, one extreme outlier (box plot)was excluded from the analysis of TG values.
Exclusionofthisoutlierdidnotinfluencethestatisticalsignificanceofthefindings.
 The difference in the primary outcome (measured FPG) between bitter gourd and
placebogroupswasanalyzedwithaCROSanalysisandgeneral linearmixedmodel.TheCROS
analysis(Freeman1989;Senn2002)isbasedontheHillsArmitageapproach(Hillsetal.1979),
whichcomparescalculatedmeanperiodandcrossoverdifferencesandcandetectatreatment
effectdespitetheexistenceofaperiodeffect.
 Second, a mixed model for fixed effect (Type III) was applied to examine treatment,
period, and carryover effects (Allison 2009). The fixed effects in thismodel were treatment
(bittergourdorplacebo),period(periodoneorperiodtwo),andcarryovereffects.Thegeneral
linearmodel detected a period effect and a significant influence of the baseline FPG on the
endline FPG (Table 7, p. 46). Thus, the change from baseline to endline was analyzed for
differencesinsteadofonlyforendlinevalues.
 Differences between baseline_1 and baseline_2 levels betweenGroup 1 and Group 2
were checked. A twosample ttest or MannWhitney test was performed if data were
consistentorinconsistentwiththenormaldistribution,respectively.




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Table 7 Type III Tests of Fixed Effects with FPG at endline (N2 + N4) as dependent variable 
Source Numerator df Denominator df F p 
Intercept 1 83 26.629 0.000 
Treatment 1 83 5.168 0.026 
Carry-over 1 83 2.105 0.151 
Period 1 83 1.354 0.248 
FPG, 
baseline,  
(N1 + N3) 
1 83 15.721 0.000 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t p 95% Confidence 
      Lower 
bound 
Upper 
bound 
Intercept 2.90982 0.563883 83 5.160 0.000 1.7883 4.0314 
Treatment 0.221769 0.097550 83 2.273 0.026 0.0277 0.4158 
Carry-over -0.141737 0.097697 83 -1.451 0.151 -0.3361 0.0526 
Period 0.116536 0.100137 83 1.164 0.248 -0.0826 0.3157 
FPG, 
baseline,  
(N1 + N3) 
0.380388 0.095936 83 3.965 0.000 0.1896 0.5712 
              FPG: fasting plasma glucose  
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3.4 Ethical considerations 
The study protocol was approved by the Institutional Review Boards of NIMR (appendix K), 
TFDA, the Kilimanjaro Christian Medical College, the Regional Medical Office in Moshi, and the 
Faculty of Medicine at Giessen University, Germany. All directly involved study personnel 
acquired a certificate on good clinical practice prior to the start of the intervention study.  
 All pre-screened and screened participants gave verbal consent to participate in the 
recruitment procedure. Participants included in the intervention study gave written informed 
consent. All were informed of their right to withdraw at any time without consequences. A data 
transfer agreement was obtained to allow the data to be analyzed outside of Tanzania. The 
study is registered under the number DRKS00005131 in the German Clinical Trial Register. 
 
4. Results 
The presentation of the results is divided into two major sections. The first section presents 
findings of the recruitment procedure in regard to health aspects and successfully enrolled 
participants. The second section presents findings of the intervention study in regard to changes 
of the examined outcome parameters such as FPG, HbA1c, and BP.   
4.1 Recruitment process 
4.1.1 Health profiles of pre-screened and screened participants 
A total of 1,256 people were pre-screened. Of these, 888 were pre-screened outside of KCRI. 
The remaining 368 people were screened at KCRI, and most were friends or relatives (n=328) of 
invited pre-screened people or were contacted previously through public announcements 
(n=40). Most people attended pre-screening activities after church services. The highest rates of 
eligible BMI and age occurred among office workers and teachers (Table 8, p. 48) 
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Table 8 Pre-screening sites outside of and inside KCRI and subsequent screening attendance 
rates. Pre-screening at KCRI took place during regular screening hours 
Pre-screening site Pre-screened 
 
n 
Eligible BMI 
and age criteria 
      n                 [%] 
Attended 
screening 
       n           [%] 
Bank 35 21 60.0 1 4.7 
Churches 595 227 38.2 131 57.7 
Convent 13 6 46.2 4 66.7 
Mosque 40 12 30.0 7 58.3 
Primary schools 62 31 50.0 22 71.0 
Police academy 90 42 46.7 17 40.5 
Revenue authority 38 29 76.3 19 65.5 
University 15 10 66.7 10 100 
Total outside KCRI 888 378 42.5 211 55.8 
Total inside KCRI 368 171 46.6 171 100 
Overall total 1256 549 43.7 382 69.6 
 
Median BMI was 27.5 kg/m² (24.1; 31.3), median age was 47.0 years (37.0; 55.0), median 
systolic BP was 125.0 mmHg (114.0; 142.0), and median diastolic BP was 83.0 mmHg (76.0; 
91.0). About 30% of participants had hypertensive BP values (Figure 9). People with high BP 
values were directed to go to their nearest health facility for further medical consultation. 
 
Figure 9 Classification of systolic (n=1218) and diastolic (n=1217) blood pressure (pre-
screening) 
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As shown in Table 9, p. 50, median BMI increased across age groups until the age of 60 years. 
The majority of the pre-screened participants were overweight or obese (Figure 10), likely 
because the research team stated that it was seeking participants with an increased body 
weight. Systolic BP increased across age groups, reaching the highest median in the oldest age 
group. Diastolic BP increased up to the age group of 50-59 years. Age was correlated with 
systolic BP (rho=0.371) and diastolic BP (rho=0.207). Body mass index correlated with systolic BP 
(rho=0.144) and diastolic BP (rho=0.244). Systolic BP was highly correlated with diastolic BP 
(rho=0.724). All correlations were significant at the level of p<0.001. Systolic and diastolic BP 
was significantly higher in obese participants than in normal-weight participants (U=52793, 
z=4.833, p<0.001, r=0.178; U=45781, z=7.296, p<0.001 r=0.270, respectively).  
 
Figure 10 Classification of body mass index of the pre-screening sample, n=1252 
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A total of 382 people had an eligible age and BMI and were further screened for the remaining 
inclusion criteria. Fasting plasma glucose and HbA1c were assessed in an additional 199 people 
who came to the KCRI pre-screening facility, but who did not meet age and BMI eligibility. Thus, 
FPG and HbA1c values were available for 581 people. Based on ADA (or WHO) criteria, 55% 
(75%) had normal, 32% (12%) had pre-diabetic, and 13% (13%) had diabetic FPG values. Fifty-
five percent of the participants with diabetic FPG values were unaware of their high glucose 
levels. These results were also detected in the regular screening sample of 382 participants 
(Table 10, p. 52). Here, 51% (73%) had normal, 35% (13%) had pre-diabetic, and 15% (15%) had 
diabetic FPG levels. Among the latter group, 60% were unaware of their high glucose levels. 
Among diagnosed diabetics (n=26), 50% were prescribed medication. However, their median 
FPG and HbA1c values were higher compared to cases in which diabetes status was unknown 
(Table 12, p. 54).  
 According to ADA criteria for HbA1c, 42% had normal, 42% had pre-diabetic, and 16% had 
diabetic HbA1c levels. In the following, only the corrected HbA1c will be presented. Concordance 
of dysglycemia between FPG and HbA1c measures was 68%, with a Krippendorff’s alpha of 
0.351, which indicates low reliability. Rates of dysglycemia were higher using HbA1c than FPG 
values. In regard to concordance of HbA1c and FPG in glycemic status, 62% were in the same 
criteria (31% had both values normal, 20% had both values pre-diabetic, and 11% had both 
values diabetic). Nineteen percent had pre-diabetic HbA1c, but normal FPG, and 12% had pre-
diabetic FPG, but normal HbA1c. The remaining 7% had other combinations. The highest 
concordance was observed in the diabetic category.  
 Forty-one percent had hypertension, defined by a systolic or diastolic BP meeting at least 
the state-I criteria. Of these, 33% had previously been diagnosed with hypertension, and one 
third of them were taking medication. The remaining 67% were unaware of their hypertensive 
BP values.  
 There was an increase in median BP and FPP values across age groups until 50-55 and 
55-59 years, respectively (Table 11, p. 53). Regarding undiagnosed diabetes, no clear trend was 
seen. Waist circumference, BP, and prevalence of hypertension increased among glycemic 
groups, reaching the peak in the diabetic group (Table 12, p. 54). This group also had the highest 
percentage of family members suffering from diabetes.   
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Table 10 Overall characteristics of screening participants (including participants with reported 
diseases and use of medication) 
                                      Group 
Variable 
All  
n=382 
Female 
n=264 
Male  
n=118 
Age [years]  47.5  
40.0; 54.0 
48  
41.0; 54.0 
45.0  
39.0; 53.0 
Smoke [yes] [%] 2 0.4 6 
Alcohol [yes] [%] 48 47 51 
Education    
  completed primary [%] 36 39 47 
  completed secondary [%] 19 18 36 
  college [%]  36 31 19 
Reporting disease [%] 36 36 36 
Regular medication [%] 22 24 19 
Body mass index [kg/m²] 29.9  
28.2; 31.1 
30.7  
29.0; 32.5 
28.3  
27.7; 31.0 
Waist circumference [cm] 94.2 (7.1) 92.4 (6.9) 98.0 (6.3) 
Diabetic family member [%] 26 29 19 
Fasting plasma glucose [mmol/L] 5.5  
5.1; 6.1 
5.5 
5.0; 6.1 
5.6  
5.2; 6.3 
 Normal FPG [%] 51 (73) 54 (74) 44 (69)  
 Impaired FPG [%] 35 (13) 32 (12) 42 (16) 
 diabetic FPG [%] 14  14  15  
    undiagnosed diabetic FPG [%] 62 66 53 
Dysglycemia [%] 49 (27) 46 (26) 56 (31) 
HbA1c  [%, (mmol/mol)] 
 
5.7 (39) 
5.4 (36); 6.1 (43) 
5.7 (39) 
5.3 (34); 6.0 (42) 
6.0 (42)  
5.4 (36); 6.3 (45) 
  normal [%] 42 (70) 45 (76) 37 (58) 
  pre-diabetic [%] 42 (14) 40 (9) 46 (25) 
  diabetic [%] 16 (16) 15 (15) 17 (17) 
Systolic BP [mmHg] 128.0  
117.0; 143.0 
127.0  
115.0; 143.0 
129.0  
119; 143.0 
Diastolic BP [mmHg] 86.0  
80.0; 93.5 
86.0  
79.0; 92.0 
87.0  
80.0; 96.3 
Hypertension type I [%] 24 26 20 
Hypertension type II  [%] 9 8 10 
Hypertension type III  [%] 8 7 10 
Overall hypertension  [%] 41 41 40 
    undiagnosed hypertension   68 65 71 
If not otherwise specified, data are expressed as median and interquartile range; waist 
circumference is presented as mean and SD; glycemic status based on fasting plasma glucose 
(FPG) is shown using American Diabetes Association (ADA) and World Health Organization 
(WHO, shown in parentheses) criteria; dysglycemia was defined by FPG ≥5.6 mmol/L (ADA) or 
≥6.1 mmol/L (WHO); HbA1c is shown using ADA criteria; BP: blood pressure, hypertension was 
defined by having at least one value in stage I, II, or III according to American Heart Association 
criteria  
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Table 13 shows results of the non-linear model with SUR. As the overall R² values were relatively 
low, with R² ranging between 0.184 and 0.248, the results should be interpreted with caution. 
Age had a greater effect on systolic BP than on the FPG and HbA1c. Waist circumference had a 
higher effect on FPG and HbA1c than on blood pressure. A similar trend was seen for BMI. Waist 
circumference showed a linear association with the dependent variables, whereas BMI showed 
a non-linear association. Correlations of dependent variables are shown in Table 14. As 
expected, systolic BP correlated highly with diastolic BP (0.804), and FPG with HbA1c (0.847). 
Systolic BP showed a medium correlation with FPG and HbA1c, whereas diastolic BP only showed 
a low correlation.  
Table 13 Results of the non-linear model using seemingly unrelated regression, n=291 for 
predictor age and body mass index, n=290 for predictor waist circumference 
   
 
Fasting plasma 
glucose 
HbA1c Systolic blood 
pressure 
Diastolic blood 
pressure 
Overall 
R² 
Predictor 
Co- 
efficientc 
p Co- 
efficientc 
p Co- 
efficientc 
p Co- 
efficientc 
p  
Agea 0.140 0.003 0.177 0.000 0.339 0.000 0.195 0.001  
Age_sqa 0.142 0.001 0.098 0.012 0.019 0.765 0.064 0.298  
R² 0.045 0.048 0.119 0.052 0.184 
WCb 0.219 0.000 0.221 0.000 0.114 0.047 0.123 0.029  
WC_sqb 0.010 0.834 0.047 0.309 0.059 0.325 0.107 0.052  
R²  0.093 0.086 0.134 0.078 0.248 
BMIb 0.142 0.003 0.130 0.005 0.008 0.893 0.026 0.682  
BMI_sqb 0.162 0.000 0.091 0.051 0.014 0.798 0.061 0.281  
R² 0.075 0.064 0.119 0.058 0.230 
WC:waist circumference, BMI:body mass index, aControlled for sex, bcontrolled for sex and age, 
cstandardized, sq:quadratic 
 
Table 14 Correlations of dependent variables controlled for age and sex, all p<0.05 
 Fasting plasma 
glucose 
HbA1c Systolic blood 
pressure 
HbA1c 0.847   
Systolic blood pressure 0.264 0.205  
Diastolic blood pressure 0.197 0.150 0.804 
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4.1.2 Enrollment rate  
After screening for all other inclusion and exclusion criteria, 74 people met all medical inclusion 
criteria and none of the exclusion criteria. Sixty-one agreed to participate in the intervention 
study (Figure 11). Two common exclusion factors for people who met the pre-diabetes criterion 
were having high BP and taking regular medication. Overall, the recruitment rate was 5% 
starting from the pre-screening phase and 16% starting from the screening phase (after found 
to have eligible BMI and age).  
 
Figure 11 Flow of recruitment procedure with enrollment rates 
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4.2 Intervention study  
Results are presented as either means ± SDs or frequencies. Results are presented for Group 1 
and Group 2 as well as for bitter gourd and placebo groups. In the latter, T1 incorporates data of 
N1 and N3 assessments and T2 incorporates data of N2 and N4 assessments (Figure 12).  
 
Figure 12 Overview on study design, treatment groups, and number of participants 
 
4.2.1 Study flow chart and participants‘ characteristics 
Sixty-one participants started the study in October 2013, with 52 finishing in March 2014. The 
dropout rate was 15%. Major reasons for dropout included traveling during the first period and 
nausea during period 2, which can be found in the CONSORT diagram (Moher et al. 2001), 
Figure 13, p. 58. Dropout was higher within Group 2, which first received placebo and then 
bitter gourd. Here, four women dropped out due to nausea and vomiting after consumption of 
bitter gourd sachets during period 2. Among the 52 participants who finished the study, not all 
had complete data for the endline assessments. Table 15, p. 59, shows baseline characteristics 
in regard to socioeconomic, demographic, and family-related data in of the overall study 
population, Group 1, and Group 2. Mean age was 47.5±8.7 for the overall study. The majority 
were married and had either at least finished primary education or gone to college. Most study 
participants were working in the business sector or were office workers. Only 4% of the study 
participants said they smoked and about half said they consume alcoholic beverages. Fifty 
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percent said they have a family member with high BP and 15% reported having a family history 
of diabetes.  
 
Figure 13 CONSORT study flow diagram of the intervention study 
 Results - Intervention study 
60 
 
Table 15 Baseline characteristics of intervention study population 
                                      Group 
Variable 
Overall 
(n=52) 
Group 1 (AB) 
(n=28) 
Group 2 (BA) 
(n=24) 
Age 47.5 ± 8.7 48.21 ± 8.4 46.63 ± 9.1 
Mean household size 4.4 ± 2.7 4.5 ± 3.1 4.1 ± 2.1 
[%] female 54 54 54 
Marital status [%]    
     Single 15 14 17 
     Married 67 68 65 
     Divorced/separated 4 7 0 
     Widowed 14 11 17 
Religion [%]    
     Christian 90 86 95 
     Muslim 10 14 5 
Educational status [%]    
     No formal education 2 4 0 
     Finished primary 38 43 33 
     Finished secondary 13 14 13 
     College 35 25 46 
     Other 12 7 4 
Occupation [%]    
     Farmer 6 11 0 
     Business sector 27 30 25 
     Student 6 7 4 
     Teacher 10 7 13 
     Nurse 6 11 0 
     Police officer 8 4 13 
     Office workers or other   37 30 45 
Motorized transportation  
  to work [%] 
56 52 61 
Smoking [%] 4 4 4 
Drinking alcohol [%] 52 39 67 
Family member with     
  diabetes [%] 
 
15 
 
18 
 
12 
Family member with 
hyptertension [%] 
50 46 54 
 
 
 Results - Intervention study 
61 
 
As shown in Table 16, there were no statistically significant differences between Group 1 and 
Group 2 at baseline N1. Unlike the HbA1c values, mean FPG values of both groups were no longer 
in the pre-diabetic range. There was a significant drop in FPG between the screening and the 
start of the intervention study (chapter 4.2.4). In addition, FPG levels from the venous blood 
samples were lower than FPG levels from the capillary blood samples. Results of capillary FPG 
levels during the intervention study are not shown. They served as a control during the regular 
checkup visits. At baseline N3, Group 1 started with a significantly lower FPG level. All other 
variables did not differ.  
Table 16 Baseline values of treatment-sequence groups at both baseline assessments 
 Period 1 Period 2 
                        Group     
                         
Variable 
Group 1 
(AB) 
Group 2 
(BA) 
 
p 
Group 1 
(AB) 
Group 2 
(BA) 
 
p 
BMI [kg/m²] 29.1 ± 2.0 30.2 ± 2.5 n.s. 29.5 ± 2.1 30.2 ± 2.8 n.s. 
FPG [mmol/L] 5.27 ± 0.44 5.40 ± 0.53 n.s. 4.98 ± 0.49 5.39 ± 0.61  0.039* 
HbA1c [%] 5.85 ± 0.43 5.85 ± 0.43 n.s. 5.86 ± 0.39  5.89 ± 0.43  n.s 
Insulin [μU/mL] 23.9 ± 16.2 25.0 ± 17.1  n.s. 27.5 ± 16.1  26.6 ± 16.1  n.s.  
HOMA-Index 6.07 ± 4.51 6.60 ± 4.41  n.s. 6.03 ± 3.38 7.50 ± 4.14 n.s. 
Chol [mmol/L] 4.26 ± 0.91 4.49 ± 0.98 n.s.  4.10 ± 1.22 4.42 ± 0.77 n.s.  
HDL [mmol/L] 0.95 ± 0.35 0.91 ± 0.24  n.s. 0.91 ± 0.31 0.85 ± 0.25 n.s. 
TG [mmol/L] 1.70 ± 0.94 1.32 ± 0.55 n.s. 1.76 ± 0.71 1.54 ± 0.40 n.s. 
Systolic BP [mmHg] 120.7 ± 15.4 122.5 ± 16.2  n.s. 115.5 ± 16.3  116.4 ± 13.1 n.s. 
Diastolic BP [mmHg] 82.5 ± 12.4 83.9 ± 9.0 n.s. 79.8 ± 10.9 80.9 ± 8.3  n.s.  
BMI: body mass index, FPG: fasting plasma glucose, HOMA: Homeostasis Model Assessment, 
Chol: cholesterol, HDL: high density lipoprotein, TG: triglycerides, BP: blood pressure, n.s. non-
significant, *Two-Samples T-Test, n: varied between parameters as follows: in Group 1: BMI 
(n=26), FPG (n=24), HbA1c (n=26), insulin and HOMA-Index (n=25), Chol, HDL, and TG (n=26), 
systolic and diastolic BP (n=25), in Group 2: BMI (n=24), FPG (n=20), HbA1c (n=24), insulin and 
HOMA-Index (n=21), Chol and HDL (n=24), TG (n=23), systolic and diastolic BP (n=25)  
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4.2.2 Effects on fasting plasma glucose, HbA1c, and insulin  
Figure 14 shows the course of FPG in Group 1 and Group 2. There was a statistically significant 
difference between Group 1 and Group 2 at assessment N2 (endline_1) with a significantly lower 
FPG level after bitter gourd supplementation than after placebo (t(44)=-2.105, p=0.041). As 
mentioned above, FPG differed between groups at assessment N3 (baseline_2) (t(44)=-2.125, 
p=0.039). During the washout period, there was a decrease in both groups that was not 
statistically significant. This decrease may be explained by a reduced food intake by study 
participants in the absence of supplementation. However, a change in food intake among 
participants during the washout period was not assessed to address this issue. 
 
Figure 14 Course of fasting plasma glucose (mean±SE) in Group 1 and Group 2  
Both the CROS analysis (t=-2.23, p=0.031, r=0.326) revealed a significant difference in the 
change of FPG between the bitter gourd group and placebo group. There was a decrease in the 
bitter gourd group and an increase in the placebo group. Overall, the treatment difference was 
0.31 mmol/l (5.6 mg/dl). This is lower than the expected clinically relevant difference of 0.56 
mmol/l (10 mg/dl). Although the calculated sample size of 54 was not achieved, the current 
sample size of 44 achieved a power of 0.82, with a medium-to-large effect size Cohen’s d of 
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0.62. The significant treatment effect was also proven by results of the general linear mixed 
model (Table 17). 
Table 17 Results of the general linear mixed model with change of FPG (T2-T1) as dependent 
variable (n=88) 
Source Numerator df Denominator df F p 
Intercept 1 84 1.524 0.220 
Treatment 1 84 6.946 0.010 
Carry-over 1 84 0.158 0.692 
Period 1 84 0.212 0.647 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t p 
95% Confidence 
Lower 
bound 
Upper 
bound 
Intercept -0.369167 0.298994 84 -1.235 0.220 -0.96375 0.22541 
Treatment 0.310167 0.117687 84 2.636 0.010 0.07613 0.54420 
Carry-over -0.046833 0.117687 84 -0.398 0.692 -0.28087 0.18720 
Period -0.054167 0.117687 84 -0.460 0.647 -0.28820 0.17986 
       FPG: fasting plasma glucose 
The change in FPG differed between subjects (Figures 15-18, p. 63-64). The participant numbers 
on the x-axis of Figure 15 correspond to the numbers on the x-axis of Figure 16, p. 63, whereas 
those in Figure 17 correspond to those in Figure 18, p. 64. Not all subjects had a decrease in FPG 
during bitter gourd supplementation. The change in FPG had a range from -1.75 to 0.92 mmol/L. 
More participants in Group 1 responded to bitter gourd supplementation than in Group 2. As 
seen in Figures 15 and 17, the drop in FPG between baseline and endline tended to be greater 
with a higher baseline FPG level. This observation was also proven in the general linear mixed 
model, where baseline FPG level had a significant effect on the outcome of endline FPG level.  
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Figure 15 Mean fasting plasma glucose levels of Group 1 at baseline_1 and endline_2  
 
 
 
Figure 16 Mean change of fasting plasma group of participants of Group 1 in period 1 
 
 Results - Intervention study 
65 
 
 
 
 
Figure 17 Mean fasting plasma glucose values of Group 2 at baseline_2 and endline_2 
 
 
 
Figure 18 Mean change of fasting plasma glucose in participants of Group 2 in period 2 
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To control for changes in food intake during the study period, a FFQ was assessed during a run-
in period and at endline_2. Results of two FFQs and derived food variety scores were available 
for 48 participants. Food variety scores did not differ between run-in and endline assessment 
(51.8±11.3 vs. 50.7±11.4). During the regular checkup questionnaires, around 3-5% of 
participants said they changed food intake during the preceding week. Some participants 
increased their intake, whereas others decreased their intake. The most common reason given 
for a change in food intake was traveling for a business trip or festivities. The physical activity 
questionnaire was used to check whether participants changed their sports activities during the 
intervention study. At run-in, 31% said they engaged in sports. At endline, 27% said they 
engaged in sports. During the regular checkup questionnaire, 2-7% of participants reported 
changes in physical activity during the previous week. The changes included either more or less 
physical activity during, for example, work, household chores, and recreation.   
 In regard to the effect on HbA1c, there was no statistically significant difference between 
the bitter gourd group and placebo group, despite a tendency for it to decrease in the bitter 
gourd group (Table 19, p. 67). The same was true for insulin levels. Both Group 1 and Group 2 
started with relatively high insulin levels (Table 18, p. 66). A Homeostasis Model Assessment 
(HOMA) index was calculated (Matthews et al. 1985). Based on a cut-off score of ≥2.5 
(Muniyappa et al. 2008), around 40% of participants were classified as having insulin resistance 
or severe insulin resistance with values similar to those among diabetes mellitus patients. 
However, this calculation does not include consideration of individual BMIs of participants. 
Insulin values were also classified using cut-offs provided by the KCRI laboratory. According to 
theses cut-offs, almost two thirds were classified as having normal insulin levels.  
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Table 18 HOMA-Index and laboratory-based cut-offs for insulin resistance at baseline 1 
                              Group 
Category      
Group 1 
(AB) n=25, [%] 
Group 2 
(BA) n=21, [%] 
HOMA-Index    
Normal insulin sensitivity (<2.5) 17 15 
Insulin resistance (≥2.5) 46 40 
Severe insulin resistance (>5.0) 37 45 
KCRI laboratory cut-offs    
Normal (2-25 [μU/mL]) 67 60 
High (≥25 [μU/mL]) 33 40 
 
4.2.3 Effects on blood lipids, anthropometrics, and blood pressure  
There were no significant differences between the bitter gourd group and the placebo group 
with regard to blood lipids, BMI, and BP (Table 19, p 67.). Mean values of TG and Chol were 
within normal ranges. Both tended to decrease in the bitter gourd group and increase in the 
placebo group, although the trends were not statistically significant. In contrast, HDL tended to 
decrease in the bitter gourd group and increase in the placebo group, although the trends were 
not statistically significant.  
 Body mass index was similar in both groups before and after treatment. Both systolic 
and diastolic BP tended to decrease in the bitter gourd and placebo groups. There was a 
significant decrease in systolic BP between screening and the start of the intervention study in 
the overall study group (chapter 4.2.6) and within Group 1 and Group 2 during period 1 (data 
not shown). As some participants reported an intake of medication during the week preceding 
assessments of venous blood samples, outcome parameters might have been influenced. Intake 
of medication was lower at both endline assessments, with 39% (n=21) taking medication at T1, 
and 17% (n=9) at T2. Reported medications included cold medicine and pain killers.   
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4.2.4 Reported adverse events and side effects  
The most-reported side effects were loose stool, diarrhea, flatulence, stomach rumbling, 
nausea, and vomiting. These side effects were reported by the bitter gourd group more often 
than the placebo group (mean numbers per side effect were n=9 vs n=5 persons). However, it is 
difficult to establish a clear causal relationship between the consumption of bitter gourd and 
the side effects, as the sachet contents were consumed after the main meal, usually dinner. 
Therefore, side effects could have also been related to food or beverage intake, in addition to 
other factors such as colds, malaria, or intake of medication. Prior to the study period, 17% 
(n=9) reported adverse events, such as headache, stomach pain, nausea, and flatulence. During 
the period 2, four female participants dropped out due to nausea and vomiting after 
consumption of bitter gourd. One person was excluded from the study after diagnosis of fatty 
liver during the washout phase. The participant had elevated GPT levels at baseline in period 1 
and was referred to a doctor for further assessment. The participant was kept in the study until 
endline in period 1, at which point GPT was still elevated. The presence of high GPT at the 
beginning implies that the intervention had no role in causing fatty liver and was acquired 
before the intervention period. The participant tested negative for hepatitis infections. An 
ultrasound revealed a fatty liver. The participant was counseled on a healthy lifestyle, excluded 
from the study, and checked again for GPT levels at the end of the study. At that point, GPT 
levels had returned to normal. The remaining dropouts were caused by traveling and, in one 
case, by follow up for lung problems acquired during the washout period. There were no serious 
adverse events during the study period. During the study period, adverse events included 
perceived side effects and reports of colds, malaria episodes, headaches, nausea, diarrhea, 
worm infections, body fatigue, and muscle pain. On average, 14% (n=7) took some kind of 
medication, such as pain or cough medication, during the week prior to the regular checkup.   
 The parameters glutamate pyruvate transaminase and plasma creatinine were assessed 
to monitor effects on liver and kidney functions. GPT and creatinine analysis excluded the 
results from one participant each, as their values were more than 3 SD higher than the mean. 
One participant with high GPT levels tested negative for hepatitis infections and received 
counseling on a healthy lifestyle. At the end of the study, his GPT levels were within the normal 
range. Further, his high levels of GPT during the first two assessments may have been due to 
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intake of antibiotics and pain killers during the week prior to venous blood sampling. The 
elevated creatinine level of one participant may have been due to a high intake of protein. All 
other values of that participant were within normal ranges. Overall, there were no significant 
differences in GPT and creatinine levels between groups at both baseline and endline (Table 20). 
Table 20 Creatinine and glutamate pyruvate transaminase values (mean±SD) and before and 
after treatment  
         Treatment 
Variable 
    Bitter gourd     Placebo   
T1 T2 Change T1 T2 Change n p 
Creatinine 
[μmol/L] 
78.9±18.5 80.9±17.7 2.0±15.8 74.5±16.6 81.8±18.5 7.6±13.6 98 n.s. 
GPT [IU/L] 25.1±10.6  25.4±12.1 0.3±11.4 25.6±10.6 24.1±7.8 -1.4±7.8 98 n.s. 
      GPT: glutamate-pyruvate transaminase, n.s.: not significant 
 
4.2.5 Glucose-lowering effect between screening and baseline assessment  
The screening for the intervention study took place between July and October 2013. The 
intervention study started in mid and late October 2013. Between these two timeframes, there 
was a significant decrease in FPG (Figure 19, p. 70) (Wilcoxon Signed Rank Test, z=-3.276, 
p=0.001) measured by capillary blood samples. The difference of 0.3 mmol/L of FPG was similar 
to the treatment difference of 0.31 mmol/L in the intervention study. 
 Systolic BP significantly decreased during the intervention study (Figure 20, p. 70), 
(paired t-test, t(51)=3.845, p=0.001). Diastolic BP also decreased, but it was not statistically 
significant. During the screening procedure, counseling on a healthy lifestyle was provided, if 
requested. No assessment of changes was performed during the time between the screening 
and the start of the intervention study.  
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Figure 19 Fasting plasma glucose of overall study group at screening and baseline_1 
 
 
 
Figure 20 Blood pressure of overall study group at screening and baseline_1 
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5. Discussion 
The discussion is divided into two major sections according to the results. The first section 
elucidates implications of health aspects and problems which were found during the screening 
process. Further, it compares the current enrollment rate to other studies and opportunities for 
health promotion activities. The second section discusses the observed hypoglycemic effect of 
bitter gourd with findings of other studies, describes glucose-lowering mechanisms and other 
bitter gourd related effects on blood lipid parameters and obesity. To illustrate the complexity 
of causes of and challenges in regard to type 2 diabetes mellitus, the conceptual framework of 
malnutrition by United Nationals International Children’s Emergency Fund (Unicef) was 
modified according to findings of the current studies and other research groups. Limitations and 
conclusion are stated for the recruitment procedure and intervention study together.   
5.1 Implications of the recruitment procedure 
5.1.1 Obesity, hypertension and elevated blood glucose values 
Recruitment for pre-diabetic volunteers was divided into two stages, a pre-screening phase and 
a screening phase, and was communicated via different channels. Due to word-of-mouth 
communication, 26% of pre-screened participants were pre-screened without prior attendance 
at information sessions, but were instead referred by already-pre-screened people. In the pre-
screening sample, rates of overweight and obesity were 37% and 32%, respectively. However, 
as people with increased body weight were encouraged to participate in the recruitment 
procedure, higher rates of overweight and obesity were expected. In the most recent Tanzanian 
Demographic Health Survey (TDHS) of 2010, 35% and 24% of women in the Kilimanjaro Region 
were overweight or obese, respectively. The TDHS did not report any data for men (National 
Bureau of Statistics et al. 2011). As obesity is linked to an increased risk of non-communicable 
diseases and negative outcomes (Dixon 2010), the high rates of obesity, especially of classes 
two and three in the current study, are a major health threat for that area. In the current study, 
obese participants had significantly higher BP values than normal-weight participants. Although 
sex was not assessed during pre-screening, an analysis of a subsample (KCRI-pre-screening 
sample, data not shown) showed that women were three times more likely to be obese than 
male participants. This phenomenon was also seen in a study conducted in Mwanza District, 
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where the obesity prevalence of women was 22% and of men was 7% in town settings (Kavishe 
et al. 2015).  
 In the current setting, eligible BMIs in the overweight and obese ranges were more 
common among more office workers and teachers than among people pre-screened at religious 
institutions. This may be linked to a more sedentary lifestyle due to office jobs or jobs with low 
physical activity (Agrawal et al. 2013). Therefore, activities promoting general health might be 
necessary to address health-related issues specific to subgroups such as office workers and 
women. However, another study detected a high BMI as a predictor for a sedentary lifestyle 
(Mortensen et al. 2006). In regard to increased BMI and a trend toward non-agricultural jobs in 
Tanzania (International Labour Office 2009), possibilities to engage in physical activity outside of 
work have to be evaluated.   
 In the current study, BMI increased with age until the age group of 40-49 years, similar 
to results reported in the TDHS (National Bureau of Statistics et al. 2011). Systolic BP increased 
with age. Diastolic BP peaked at the age group of 40-49. Both were correlated with BMI, 
although diastolic BP was more highly correlated with BMI than systolic BP. Other studies have 
demonstrated age- and BMI-related increases in systolic and diastolic BP (Mungreiphy et al. 
2011) and as predictors, independently from each other, for hypertension (Gebreselassie et al. 
2015).  Overall, 30% of pre-screened participants were classified as hypertensive, which is 
similar to the WHO's age-standardized estimate of 29% (WHO 2014). The majority was unaware 
of their hypertensive BP values, which was also seen in other settings (Kavishe et al. 2015) and 
needs to be addressed in future health programs.   
 Although the screening sample was not representative and had no diagnostic character, 
there were high rates of pre-diabetic and diabetic FPG values (35% and 14%, respectively) and 
HbA1c values (42% and 16%, respectively), according to ADA criteria. Around 60% were unaware 
of their diabetic FPG levels, which was lower than the estimate of 67% in Sub-Saharan Africa 
(IDF 2015). In other studies, rates of undiagnosed diabetes ranged from 18% to 62% (Heianza et 
al. 2012; Kavishe et al. 2015; Mayega et al. 2013). The overall high prevalence of diabetes 
among the screening sample can be explained by the high number of diabetics who came to the 
screening, with many reporting that they thought they were coming to a new diabetes clinic 
offering free measurements. In the subgroup of treated diabetic patients, median HbA1c was 
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8.5% (69 mmol/mol), higher than the recommended target level of 7% (65 mmol/mol) for 
glycemic control among diabetic patients (ADA 2014). In addition, FPG and HbA1c levels among 
people with diabetic FPG (treated and untreated; known and unknown) were high. This, 
together with the high levels of hypertension, indicates that urgent action is needed to improve 
health outcomes among people afflicted by diabetes.  
 As seen in other studies (Mayega et al. 2014; Mayega et al. 2013; Bao et al. 2015; Xu et 
al. 2013), pre-diabetic prevalence rates varied between ADA and WHO criteria. In the current 
study, ADA criteria resulted in a 2.7 times higher prevalence rate than WHO criteria. The WHO 
had previously stated that lowering the threshold for IFG from 6.1 mmol/L to 5.6 mmol/L would 
result in a higher rate of pre-diabetes with a lack of evidence for better health outcomes (WHO 
2006). The prevalence of 35% according to ADA was more than three times higher than the 
national prevalence of 10.3% of pre-diabetes defined as IGT (IDF 2013). According to WHO 
criteria, prevalence of pre-diabetes was 12%. The higher rates may be due to the tailored 
screening of people with higher BMI and age, as well as differences in IFG and IGT. People with 
IFG may not necessarily have IGT, and vice versa, which may be due to different pathological 
pathways and other factors (Perreault et al. 2014). In a study by Zhang et al., isolated IFG was 
prevalent among 28% of study participants, whereas 5.1% had isolated IGT and 10.3% had both 
IFG and IGT (Zhang et al. 2015). In a study by Chilelli et al., isolated IFG was seen in 27.1%, 
isolated IGT in 6.8%, and both in 4.6% (Chilelli et al. 2014). Both applied ADA cut-off values for 
IFG, which may explain the higher rates of pre-diabetes based on FPG than based on glucose 
tolerance. The current study did not assess glucose tolerance. Measurement of glucose 
tolerance is not always feasible in resource-poor or work settings, as it is cumbersome and time 
consuming for the participant, especially in a screening setting (Anand et al. 2003; Mayega et al. 
2014) . In the current screening, which had no diagnostic character, the measurement of FPG to 
define glycemic status was quick and easily administered by health staff.  
 Yudkin and Montori (2014) expressed concerns about the new ADA cut-offs and the 
subsequent increase in pre-diabetes diagnoses, as well as the overall concept of categorizing 
people as pre-diabetic. They argue that it diverts attention from high risk people or diabetic 
patients who need medical attention (Yudkin et al. 2014). Rates of pre-diabetes may be even 
higher when an HbA1c cut-off of 5.7 to 6.4% is applied (Yudkin et al. 2014), which was also the 
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case in the current screening in which 42% of participants had pre-diabetic HbA1c values 
compared to 35% for IFG (ADA criteria) or 12% for IFG (WHO criteria). These results were also 
seen in other studies, where rates of pre-diabetes using HbA1c measures were higher than using 
measures of FPG or 2-hour plasma glucose (Mayega et al. 2014; Botana Lopez et al. 2012). 
However, some other studies showed comparable rates (Costa et al. 2013), and some missed 
cases or showed lower rates when applying ADA defined HbA1c cut-offs (Bhansali et al. 2012; 
Zhou et al. 2010).  
 In the current screening, diabetic glucose had the highest concordance between HbA1c 
and FPG, although the overall Krippendorff’s alpha was low (0.351). In a cross-sectional study at 
a primary care setting in Spain (Costa et al. 2013), HbA1c measurement revealed a significantly 
lower diabetes prevalence (3.2%) compared to 2-hour plasma glucose testing (9.2%), but was 
similar to FPG (3.1%). In a population-based survey in a rural district of Uganda, diabetes 
prevalence rates were 4.8% according to FPG and 11.3% according to HbA1c. Despite the low 
agreement between HbA1c and FPG, they detected a high agreement among negatives (normo-
glycemic FPG and normal HbA1c) (Mayega et al. 2014). Specifying universal cut-off points for 
HbA1c may be difficult due to ethnic differences, with higher levels observed among people of 
African origin (Selvin et al. 2011; Ziemer et al. 2010), as well as other influencing factors 
(Dubowitz et al. 2014). However, it has been argued that HbA1c is a valid predictor for diabetes, 
including undiagnosed cases, but should not be used to identify pre-diabetes (WHO 2011).  
 In regard to risk factors for increased glucose or BP values, the current study showed 
similar results to other assessments (Veghari et al. 2014; Patil et al. 2012; Okosun et al. 1998; 
Davidson et al. 2014) with WC and BMI being predictors for FPG and BP. The association 
between WC and dependent variables (FPG, HbA1c, BP) was linear, whereas it was non-linear for 
BMI. The current study had an upper BMI limit of 35 kg/m² whereas a higher limit would be 
needed to assess this issue of a non-linear association between BMI and FPG and BP. In a study 
in Brazil, mean BMI did not differ between glycemic groups, but WC was significantly higher 
among the pre-diabetic group than the normo-glycemic group (Franco et al. 2014). In another 
study, obese people were two times more affected by dysglycemia than normal-weight people 
(Mayega et al. 2013). The measurement of WC as a low cost and noninvasive method might 
serve as a good screening tool to assess risk for dysglycemia in that region.  
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 In the current study, there was no difference in BP or glycemic status between alcohol 
consumers and non-consumers. Overall, alcohol consumption was similar to national data 
(WHO 2014). Smoking rates were considerably lower with 6% and 0.4% among men and 
women, compared to national data of 28% and 4%, respectively (WHO 2014). Thus, no 
association with tobacco use could be calculated. A study by Mayega found no association of 
abnormal glucose regulation with sex, age group, hypertension, tobacco use, or harmful alcohol 
use (Mayega et al. 2013). 
5.1.2 Comparison of enrollment rates and health related activities  
The overall enrollment rate was 5% from the pre-screening phase and 16% from the screening 
phase. The 16% corresponds to 13-14 participants per month. Several studies for the Diabetes 
Prevention Program  were conducted in working environments and resulted in recruitment 
rates of 10-11 participants per month (Ackermann et al. 2008), 14 participants per month 
(Blackwell et al. 2011), 45 participants per month (Taradash et al. 2015), and 59 participants per 
month (Amundson et al. 2009). Although 74 screened participants were eligible for the current 
intervention study, only 61 started the trial. Queries for non-participation were not conducted. 
In other diabetes-related programs, a common reason given for non-participation was time 
conflicts (Toobert et al. 2002; Taradash et al. 2015). The recruitment rate might have been 
higher with less strict BMI and age criteria. However, this would have lowered the homogeneity 
of the sample population of the subsequent intervention study.  
 Communication for scheduling appointments and reminding participants to fast in 
advance was done via phone calls and text messages. Since almost everyone owned a cell 
phone or had a relative or friend with a cell phone, this proved to be an effective and 
convenient mode of communication that could be used in future health programs. Public and 
private institutions were generally open to collaboration and allowed members of the research 
team to introduce themselves and the project, and also allowed their workers to participate in 
the screening. In addition, support was provided through official channels such as the Regional 
Medical Office. The positive behavior shows that private and public institutions are open to 
health-related issues and might be approached for future health programs and activities. 
 Whether screening for diabetes will be feasible in that region needs to be discussed 
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among health and policy institutions. It has been argued that screening for diabetes is not 
justifiable, as it does not meet all criteria for disease screening (Diabetes Care 2002) as defined 
by WHO (Wilson, J. M.G. et al. 1968). One major criticism is that screening should only be done 
if medical treatment is available (Wilson, J. M.G. et al. 1968; National Cancer Control Policy 
Australia 2015). Assessments indicate that there are insufficient medical supplies and treatment 
facilities in Tanzania (Peck et al. 2014a; Ministry of Health and Social Welfare, Tanzania 2013; 
Robertson et al. 2015), which would speak against performing screening. However, because the 
progression of pre-diabetes to diabetes mellitus type 2 and the outcomes of diabetes mellitus 
type 2 might be modified with lifestyle changes (Burr et al. 2010; Sato et al. 2007), especially 
increased physical activity, a screening of pre-diabetes or diabetes may be worthwhile. 
Promotion of a healthy lifestyle and related activities should be strived for generally, but could 
also be conducted with the help of screening, as people might be more motivated to change 
eating and physical activity habits after they know their own health status. In the current 
setting, FPG significantly dropped among some study participants from the time point of the 
screening (5.97 (±0.47) mmol/L) to the start of the baseline study (5.67 (±0.61) mmol/L). During 
the screening process, counseling on a healthy lifestyle was provided to participants if 
requested. The provided counseling may have led to a change in behavior and a drop in FPG. 
Nevertheless, in regard to the region's high levels of elevated BP and glucose levels, health 
promotion strategies should be established in addition to screening activities. Such promotion, 
screening, and education activities are already incorporated at an exhibition of KCMC during the 
World Diabetes Day (Figure 21 and Figure 22, both p. 77), but need to be extended.  
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Figure 21 Members of the public obtaining educational material on diabetes at the KCMC 
exhibition during Diabetes Day 2013 
 
 
Figure 22 Measurement of fasting plasma glucose and HbA1c at KCMC exhibition during 
Diabetes Day 2013
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5.2 Intervention study effects 
5.2.1 Glucose lowering effect compared to other studies  
In the current cross-over study, bitter gourd supplementation had a glucose-lowering effect on 
FPG compared to placebo. The effect was associated with the baseline FPG level. Participants 
with higher FPG levels at baseline showed a greater change in level than those with lower FPG 
levels. Therefore, bitter gourd may be more effective in lowering glucose levels when they start 
at high values.  
 Although participants were screened for pre-diabetes, some had normal FPG levels at 
baseline. This may have affected the outcome of the study and reduced the glucose-lowering 
effect of bitter gourd. Although not statistically significant, the decrease during the washout 
period may be explained by a reduced food intake during the absence of a supplementation. 
However, no data was collected during the washout period. Fewer participants responded to 
bitter gourd treatment in period 2 than in period 1 (Figure 15, p. 63 and Figure 17, p. 64). This 
may also be related to the lower FPG levels at baseline_2 compared to baseline_1.  
 With regard to HbA1c and insulin, no differences were seen between bitter gourd and 
placebo groups. Overall, insulin levels and insulin resistance based on the HOMA index seemed 
to be high among the study participants. As BMI was not considered in the current calculation of 
HOMA-IR scores, the actual cut-off point to classify insulin resistance may be higher. HOMA-IR 
cut-off values do not only change with BMI, but also vary between populations (Gayoso-Diz et 
al. 2013; Stern et al. 2005). Further, insulin values can vary depending on the laboratory tests 
applied (Manley et al. 2008). Insulin resistance according to the HOMA index and laboratory 
base cut-offs differed in the study population. This difference and the high insulin levels need 
further investigation in future studies.  
 The current study showed a glucose-lowering effect of bitter gourd among pre-diabetics. 
Most other studies that examined anti-diabetic effects of bitter gourd were performed with 
diabetes mellitus patients, who had higher baseline FPG and HbA1c levels. Thus, comparisons to 
the current study results have to be made cautiously. 
 The current study used whole fruit powder mixed with water as a supplementation. 
Whole bitter gourd fruit was also used in other studies, either in tablet form (John et al. 2003), 
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capsule form (Tsai et al. 2012; Srivastava et al. 1993), or aqueous extract form (Srivastava et al. 
1993). John et al. (2003) examined the effects of a supplementation of 6 g dried powder per day 
for four weeks as an adjunct therapy for 26 diabetic patients. Although study participants had 
higher baseline FPG levels of 8.33±1.49 mmol/L compared to the current setting, and the 
dosage was more than two times higher, there were no statistically significant effects on FPG, 
postprandial plasma glucose, and fructosamine levels, compared to placebo. The authors 
assume that patients might have maintained their normal dietary regimens or intake of OAD 
(John et al. 2003).  
 Srivastava et al. (1993) examined effects of a supplementation of 100 mL aqueous 
extract per day, equivalent to 100 g cooked fruit in 200 mL water, for seven weeks among 
patients with mild to severe diabetes. No information was provided about concomitant 
treatment with hypoglycemic agents. The supplementation significantly dropped postprandial 
glucose levels by 54%, and decreased HbA1c levels from a baseline of 8.37±0.39% to 6.95±0.46%. 
In addition to supplementation with the aqueous extract, five diabetic patients were 
supplemented with 5 g fruit powder per day in tablet form for three weeks. After this 
supplementation, no anti-diabetic effect was observed (Srivastava et al. 1993).  
 Another study, which included the whole fruit of bitter gourd, was conducted by Tsai et 
al. (2012) with participants who met at least three criteria for metabolic syndrome. Here, 4.8 g 
of fruit powder capsules per day were consumed by eligible participants over three months. The 
authors reported an improvement in logHOMA, Quicki, and McAuley values, although they were 
not statistically significant. Waist circumference was significantly reduced from baseline after 
three months (-2.50±0.86 cm), as was the incidence of metabolic syndrome (19%). Follow up 
visits showed that these results were sustained one month after the end of the 
supplementation phase, but not further (Tsai et al. 2012).  
 Two studies examined effects of bitter gourd fruit pulp on diabetic patients with no 
adjunct therapy (Welihinda et al. 1986; Fuangchan et al. 2011). Wehlihinda et al. (1986) 
examined effects of a single dosage of 100 mL clear bitter gourd juice on type 2 diabetes 
patients. Participants received either bitter gourd or placebo 30 minutes before receiving a 
glucose load. The bitter gourd juice significantly improved glucose tolerance and revealed a 
significantly lower area under the curve than placebo (187.0 cm vs. 243.6 cm, respectively). This 
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study also showed that there were responders and nonresponders to bitter gourd treatment. In 
the study by Wehlihinda et al. (1986) 73% (n=13) responded to bitter gourd and 27% (n=5) did 
not. This response rate is higher than in the current setting, where around 60% responded to 
bitter gourd supplementation. In the current study, nonresponding may be due to a normal FPG 
level or genetic factors in participants. The current study also aimed to conduct single 
nucleotide polymorphism (SNP) analysis, in which genetic variations between responders and 
nonresponders are compared. However, the quality of DNA samples was insufficient for SNP 
analysis. A new collection of DNA samples of study participants, planned for 2016, may provide 
insights into differences between responders and nonresponders. The observation of 
nonresponders has also been reported in studies using oral hypoglycemic drugs (Groop et al. 
1986; Khan et al. 2015).  
 Fuangchan et al. (2011) examined the effects of 500 mg, 1000 mg, and 2000 mg of bitter 
gourd fruit pulp, or 1000 mg of metformin, per day for four weeks on newly diagnosed type 2 
diabetic patients in a placebo-controlled trial. There were no statistically significant effects of 
the 500 mg and 1000 mg dosages. Supplementation of 2000 mg bitter gourd significantly 
reduced fructosamine levels from a baseline of 18.14±2.93 mmol/L to 17.57±2.67 mmol/L. This 
glucose-lowering effect, however, was smaller than with metformin supplementation, during 
which fructosamine levels dropped significantly from 17.11±3.78 mmol/L to 16.18±2.89 mmol/L. 
In addition, metformin significantly reduced FPG and 2-h plasma glucose levels, whereas bitter 
gourd supplementation did not. Bitter gourd supplementation did not show any effect on these 
outcomes (Fuangchan et al. 2011).   
 Tsongia et al. (2004) studied the effect on type 2 diabetic participants of 200 mg 
methanolic bitter gourd extract taken twice per day (BD) and OAD taken for seven days. The 
study was divided into two stages and three groups. In the first weeklong stage, participants 
received either 0.5 g metformin BD, 5.0 g glibenclamide, or a combination of both (0.5 g 
metformin BD + 5.0 g glibenclamide BD). In the second weeklong stage, study groups received 
200 mg bitter gourd extract BD and half the standard dosage of the metformin, glibenclamide, 
or combination. At the end of week two, bitter gourd supplementation corresponded to 
significantly lower fasting and postprandial glucose levels compared to only the drug treatment 
in week one. Specifically, bitter gourd increased the glucose-lowering effect of half the standard 
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metformin dosage on FPG and postprandial plasma glucose by 10% and 17%, respectively. 
Further, it enhanced the glucose-lowering effect of half the standard dosage of glibenclamide 
on these parameters by 11% and 15%, respectively. The authors assume a synergistic effect of 
OAD and chemical constituents of bitter gourd, such as alkaloids, sterols, glycosides, and tannins 
(Tongia et al. 2004).  
 Dans et al. (2007) examined effects of 3 g bitter gourd (Charantia Ampalaya Capsules©) 
taken for three months on newly or poorly controlled type 2 diabetic cases. The study group did 
not find any statistically significant differences between the bitter gourd and placebo groups 
with regard to FPG, HbA1c, body weight, or total cholesterol (Dans et al. 2007).  
 Zänker et al. (2012) investigated effects of 1 g bitter gourd extract in capsule form 
(Glucokine®) taken for four months on type 2 diabetes mellitus participants (with or without 
concomitant oral hypoglycemic drug therapy). The study included three arms. In one arm, 
participants received 1 g of bitter gourd. In the second arm, participants received 1 g bitter 
gourd in combination with chromium and zinc supplementation capsules. In the third arm, 
participants received a placebo. There was no effect or treatment difference between groups 
with regard to FPG. However, there were statistically significant decreases in HbA1c levels 
compared to baseline within the bitter-gourd-only group and the placebo group. The bitter 
gourd group showed a larger effect than the placebo group (6.47±0.63% to 6.28±0.57% vs. 
6.51±0.65% to 6.41±0.76%) (Zänker et al. 2012).  
 Kochhar and Nagi (2011) examined the effects of a raw or cooked combination of bitter 
gourd, fenugreek seeds, and jambu seeds (all in equal amounts), on type 2 diabetic patients 
with or without OAD therapy. This study was divided into two phases. In the first phase, 1 g per 
day was given to diabetic patients in either raw (capsule) or cooked (biscuit) form for 45 days. In 
the second phase, the dosage was doubled for 45 days. After the first phase, there was a 
statistically significant drop in FPG and postprandial plasma glucose compared to baseline in 
both groups, with a larger effect in the group receiving the raw mixture. In this group, FPG levels 
dropped from 9.95±0.34 mmol/L to 7.85±0.28 mmol/L and postprandial plasma glucose levels 
dropped from 13.41±0.35 mmol/L to 9.73±0.31 mmol/l. In the other group, FPG levels dropped 
from 9.43±0.31 mmol/L to 7.90±0.35 mmol/L and postprandial plasma glucose levels dropped 
from 11.4±0.28 mmol/L to 9.83±0.27 mmol/L. After the second phase, both outcomes further 
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significantly decreased to 5.89±0.21 mmol/L and 7.52±0.19 in the first group and 6.55±0.30 
mmol/L and 9.67±0.25 mmol/L in the second group, respectively. In addition, after phase two, 
glucose excretion was lower in fasting and postprandial urine samples compared to baseline. 
The study group also assessed effects of bitter gourd supplementation on the use of OAD and 
found a decrease in their usage from 88% at baseline to 33% at the end of phase two (Kochhar 
et al. 2011).  
 In the presented studies, bitter gourd supplementation did not always have 
hypoglycemic effects in diabetic patients. This may be due to different designs, dosages, 
durations, outcome measures, and statistical analyses, as well as the characteristics of the study 
subjects, which are summarized in Table 21. Unlike the current study, many of the others only 
included a small number of participants and were not placebo controlled. Another advantage of 
the current study was the cross-over design, which reduces the between-subject variability.  
Table 21 Overview on human studies with bitter gourd among pre-diabetic or diabetic 
patients (adapted from (Habicht et al. 2014) 
Study design 
[reference] 
Study subjects Dosage (all oral) Duration  Preparation Effects  (p<0.05) 
Randomized 
single-blind 
placebo-
controlled 
cross-over 
44 Pre-diabetics 2.5 g per day  8 weeks Dried whole fruit 
powder mixed 
with 150 ml 
water 
Glucose-lowering 
effect on fasting 
plasma glucose  
Open-labeled 
single-arm study 
(Tsai et al. 2012) 
42 patients 
diagnosed with 
metabolic 
syndrome 
4.8 g per day 3 months Whole fruit 
powder capsules 
Decreased 
incidence rate of 
metabolic 
syndrome among 
study population;  
Lower waist 
circumference 
Randomized 
single-blind 
placebo-
controlled      
(John et al. 2003) 
50 type 2 diabetic 
patients 
6 g per day  4 weeks  Dried whole fruit 
powder pressed 
to tablets / 
riboflavin as 
placebo 
No effect 
Not placebo-
controlled   
(Tongia et al. 2004) 
15 type 2 diabetic 
patients 
200 mg per day 
in addition to 
metformin, 
glibenclamide, or 
both 
7 days Methanolic fruit 
extract  
Lower fasting and 
postprandial 
glucose levels 
compared to the 
drug treatment 
alone 
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Table 21 continued: Overview on human studies with bitter gourd among pre-diabetic or 
diabetic patients (adapted from (Habicht et al. 2014) 
Study design 
[reference] 
Study subjects Dosage (all 
oral) 
Duration  Preparation  Effects                                
(p<0.05)  
Randomized 
double-blind 
placebo-
controlled 
(Dans et al. 2007) 
40 newly 
diagnosed 
type 2 diabetic 
patients or 
patients with 
poor blood 
glucose 
control 
3 g per day in 
addition to 
standard 
therapy 
3 months Charantia Ampalaya 
Capsules© and 
placebo 
No effect  
Not placebo-
controlled 
(Srivastava et al. 
1993) 
Diabetic 
patients (7 
patients tested 
extract / 5 
patients tested 
tablets) 
100 mL 
(extract) or 
three times a 
day 5 g (tablet)  
7 weeks  
(extract) or 
 3 weeks  
(tablet) 
Aqueous extract / 
fruit powder as tablet 
Lower postprandial blood 
glucose and HbA1c levels 
after treatment with 
bitter gourd extract; 
No effect after treatment 
with bitter gourd tablets 
Not placebo-
controlled 
(Welihinda et al. 
1986) 
18 newly 
diagnosed 
type 2 diabetic 
patients 
without anti-
diabetic drugs 
100 mL  Single dosage Clear juice from the 
flesh of Sri Lankan 
bitter gourd variety / 
distilled water as 
control 
Improved glucose 
tolerance;  
Indication for possible 
non-responders 
Randomized 
double-blind 
active-
controlled, 
dosage was 
placebo-
controlled 
(Fuangchan et al. 
2011) 
143 newly 
diagnosed 
type 2 diabetic 
patients 
500 / 1000 / 
2000 mg per 
day or 1000 
mg metformin 
per day  
4 weeks Capsules of dried fruit 
pulp powder or 
metformin / roasted 
rice powder and 
lactose as placebo 
Reduced fructosamine 
levels only with 2000 mg 
per day  
Not placebo-
controlled 
(Kochhar et al. 
2011) 
60 type 2 
diabetic 
patients free 
from serious 
complications 
45 days 1 g per 
day + 45 days 
2 g per day  
90 days Mixed powder of 
bitter gourd fruit, 
fenugreek seeds, and 
jambu seeds in either 
raw (capsule) or 
cooked (biscuit) form 
Lower fasting and 
postprandial glucose 
levels in blood and urine;  
Reduced intake of oral 
hypoglycemic drugs;  
Raw powder was more 
effective 
Double-blind 
placebo-
controlled 
(Zänker et al. 
2012) 
97 type 2 
diabetic 
patients with 
or without oral 
anti-diabetic 
therapy 
1 g per day  4 months Water soluble bitter 
gourd extract 
(Glucokine®) with or 
without chromium 
and zinc 
supplementation in 
capsules  
Decreased HbA1c after 
bitter gourd treatment 
without chromium and 
zinc supplementation  
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5.2.2 Mechanisms of glucose lowering effects of bitter gourd 
The observed hypoglycemic effects in human studies are due to glucose-lowering components 
in bitter gourd. Many different compounds in bitter gourd have been investigated in cell and 
animal studies (Joseph et al. 2013; Singh et al. 2011; Habicht et al. 2014). Three major 
mechanisms, shown in Figure 23 are responsible for the glucose-lowering effect by decreasing 
intestinal glucose absorption, increasing insulin secretion, and increasing glucose uptake in 
peripheral tissues (Habicht et al. 2014), shown in Figure 23. Other examined mechanisms 
include an inhibition of adipocyte differentiation (Nerurkar et al. 2010) and a suppression of key 
gluconeogenic enzymes (Shibib et al. 1993; Singh et al. 2011), among others (Joseph et al. 
2013). Some of the isolated compounds in bitter gourd responsible for hypoglycemic effects are 
p-insulin (polypeptide-p), momordicosides, oleanic acid, trehalose, and momordin. The p-
insulin, revealed an insulin-like effect in type 1 and type 2 diabetic patients after subcutaneous 
administration (Khanna et al. 1981). In in-vitro, ex-vivo, and animal studies, momordicoside S 
and T showed increased glucose tolerance and improved insulin sensitivity (Tan et al. 2008). 
Oleanolic acid increased the release of intestinal glucagon-like-peptide-1 (GLP-1) (Huang et al. 
2013), trehalose decreased postprandial blood glucose levels (Matsuur et al. 2002), and 
momordin activated peroxisome proliferator-activated receptor-γ (PPAR-γ) (Sasa et al. 2009).  
           
PPAR: peroxisome proliferator-activated receptor, PTP 1B: protein tyrosine phosphatase 1B, AMPK: 
adenosine monophosphate-activated protein kinase, GLP-1: glucagon-like-peptide-1 
Figure 23 Overview on hypoglycemic mechanisms of bitter gourd constituents, adapted from 
(Habicht et al. 2014) 
Decreased  
intestinal glucose absorption 
• GLP-1 secretion 
• β-cell protection 
/recovery 
Increased  
insulin secretion 
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5.2.3 Effects on body weight, blood pressure, and blood lipids  
In the current study, there were no significant differences with regard to BMI, blood lipid 
parameters, and BP between bitter gourd and placebo groups. This was similar to the study by 
Dans et al. (Dans et al. 2007), where no effect was observed on total cholesterol and body 
weight. The absence of an effect on HDL, Chol, and TG in the current setting might be due to the 
fact that blood lipids of study participants were mostly within normal ranges.  
In several animal studies (Table 22), bitter gourd treatment was shown to improve lipid profiles 
of diabetic and obese mice and rats (Ahmed et al. 2001; Chaturvedi et al. 2004; Nerurkar et al. 
2008; Gadang et al. 2011).  
Table 22 Effects of bitter gourd on lipids in diabetic and obese rats and mice (Alam et al. 2015)  
Model 
[reference] 
Dosage Effects 
STZ-induced 
diabetic rats  
(Ahmed et al. 2001) 
10 mL 100% fruit 
extract per kg body 
weight per day for 
10 weeks 
Decreased elevated level of plasma cholesterol, 
triglycerides, and phospholipids 
Diabetic rats 
(Chaturvedi et al. 2004) 
140 mg per kg body 
weight for 30 days 
Decreased triglycerides and low-density 
lipoprotein 
Female C57BL/6 
mice fed with 
HFD 
(Nerurkar et al. 2008) 
1.5% freeze-dried 
bitter gourd juice 
with diet 
Normalized triacylglycerol, cholesterol and NEFA; 
Normalized AST, ALT, and ALP in plasma; 
Decreased ApoB secretion and modulated 
phosphorylation status of insulin resistance and 
its downstream signaling molecules 
Female Zucker 
rats 
(Gadang et al. 2011) 
3.0% (wt=wt) bitter 
gourd seeds 
Increased expression of PPAR-γ in the WAT; 
Decreased total cholesterol, and LDL cholesterol, 
and increased HDL cholesterol; 
Downregulated expression of PPAR-γ, nuclear 
factor-kB, and interferon-γ mRNA in heart tissue 
NEFA: non-essential fatty acid, AST: Aspartate transaminase, ALT: alanine transaminase, ALP: 
Alkaline phosphatase, ApoB: apolipoprotein B, PPAR: peroxisome proliferator-activated 
receptor, -kB: kappa-light-chain-enhancer, mRNA: messenger ribonucleic acid 
 
In the current study, participants were asked to not change their eating and physical activity 
habits during the study period, and therefore avoid significant changes in BMI due to dieting or 
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increased physical activity during bitter gourd consumption. In animal studies (Table 23), bitter 
gourd treatment showed a significant reduction in body weight gain in groups treated with 
bitter gourd compared to placebo (Chan et al. 2005; Huang et al. 2008; Klomann et al. 2010). 
Tsai at al. (Tsai et al. 2012) also found no effect on BP outcomes.  
Table 23 Effects of bitter gourd on body weight, obesity, and adiponectin dysfunction, 
adapted from (Alam et al. 2015) 
Model 
[reference] 
Dosage Effects 
High-fat-diet- 
induced fat rats 
(Chan et al. 2005) 
0.75% and 1.5% 
extracts 
Decreased body weight, visceral fat mass, plasma 
glucose, and triacylglycerole 
Increased plasma catecholamines 
Male C57BL/6J 
mice, 5 weeks old 
(Shih et al. 2008) 
0.5 g/kg per day 
1.0 g/kg per day P-
fraction extract 
(whole fruit incl. 
pulp and seed) or 
0.2 g/kg per day 
1.0 g/kg per day G-
fraction extract 
(whole fruit) 
Decreased body weight and visceral fat 
Decreased plasma glucose, triglycerides, and 
total cholersterol 
Increased free fatty acid 
Increased mRNA expression of leptin, PPAR-γ, 
PPAR-α, and decreased expression of resistin 
Male Wistar rats 
fed high-fat diet 
(Huang et al. 2008) 
5% (w/w) powder Decreased body weight and adipose tissues 
Decreased triacylglycerol and cholesterol 
Increased adiponectin 
Overweight rats  
(Farhat Bano 2011) 
Aqueous extract  
2 mL per day 
Reduced elevated body weight gain and 
cholesterol, triglycerides, and low-density 
lipoprotein cholesterol 
Increased high density lipoprotein cholesterol 
PPAR: peroxisome proliferator-activated receptor, mRNA: messenger ribonucleic acid 
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5.2.4 Adverse events and side effects compared to other bitter-gourd studies and diabetic 
treatments  
In the current study, adverse effects after bitter gourd consumption were gastric complaints, 
flatulence, loose stool, diarrhea, headache, nausea, and vomiting. No hypoglycemic events were 
reported. During the period 2, four female participants dropped out due to nausea and vomiting 
after consumption of bitter gourd. This might be linked to the slightly bitter taste of the fruit, 
despite the blinding, and a possible development of an aversion to it. The palatability of bitter 
gourd may be improved to avoid the bitter taste and related side effects. However, as bitter 
gourd was consumed after the main meal, it is difficult to identify a clear causal relationship 
between its consumption and side effects or adverse events. In addition, perceived side effects 
may be linked to concurrent diseases and intake of medications during the study period. The 
low dropout rate of 15% during the six-month study period demonstrates participants' interest 
in their health and well-being, as well as a tolerance for the study product.   
 The side effects reported in the current study were also reported in other studies. Within 
these studies, the most common adverse events reported were gastrointestinal complaints, 
headache, dizziness, and nausea. These adverse events did not differ compared to those for 
placebo or OAD (Tsai et al. 2012; Fuangchan et al. 2011; Dans et al. 2007).  
 In the current setting, there was no significant influence of bitter gourd supplementation 
on creatinine and GPT levels. This result is similar to observations in the other studies that 
aspartate aminotransferase or alanine aminotransferase were not altered by bitter gourd 
treatment (Fuangchan et al. 2011; Tsai et al. 2012; Dans et al. 2007; Zänker et al. 2012). Further, 
in other studies, no changes were seen in sodium and potassium levels (Dans et al. 2007; Tsai et 
al. 2012), alkaline phosphatase, or glutamyl transferase (Tsai et al. 2012; Zänker et al. 2012).  
 In the current trial and presented studies, bitter gourd as a medicinal plant seemed to be 
safe for consumption by study subjects. However, consumption of bitter gourd is not 
recommended for pregnant and lactating women, because animal studies have shown negative 
effects on fertility and because it has been used as an abortifacient agent (Grover et al. 2004; 
Raman, A. et al. 1996). Further, a glycol alkaloid known as vicine has been isolated from bitter 
gourd seeds (Haixia et al. 2004). Vicine, also found in fava beans, can cause hemolytic anemia 
after consumption by people with G6PD deficiency, so consumption by such people is not 
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recommended. However, so far, there have not been any reports of hemolytic anemia after 
bitter gourd consumption (Joseph et al. 2013).  
5.2.5 Glucose lowering effect due to behavior change?  
As reported in chapter 4.2.5, there was a significant decrease in FPG between screening and 
baseline_1. Figure 24 shows that all participants had a pre-diabetic FPG as required by inclusion 
criteria at screening, but that some had a normal FPG at baseline.  
 
Figure 24 Boxplot of fasting plasma glucose of overall study group at screening and baseline_1 
As shown in Table 24 p. 89, there were no significant differences in HbA1c or BMI. However, 
there was a significant decrease in systolic BP. These effects may be due to behavioral changes. 
During the screening, counseling on a healthy lifestyle was provided to participants, if 
requested, and included recommendations to increase vegetable intake, moderate alcohol 
intake, and engage in physical activity. However, as no data were collected on whether 
participants changed their lifestyle after being identified as having pre-diabetic glucose level, no 
clear conclusions can be drawn. Nonetheless, lifestyle changes may be a feasible way to 
improve FPG among pre-diabetic people. A study on the effect of lifestyle interventions on 
glycemic status is needed in this study area to address the issue. 
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Table 24 Various variables of overall study group (n=52) at screening and baseline_1 
                             Time point 
Variable  
Screening Baseline_1 p 
Fasting plasma glucose, mmol/L 5.97 ± 0.45 5.67 ± 0.61 0.001 
HbA1c, % 5.87 ± 0.41  5.84 ± 0.43 n.s. 
Body mass index, kg/m² 29.8 ± 2.4 29.7 ± 2.3 n.s. 
Systolic blood pressure, mmHg 127.8 ± 15.0 122.4 ± 15.8 0.001 
Diastolic blood pressure, mmHg 85.5 ± 9.3  83.6 ± 10.8 n.s. 
 
In other studies, lifestyle interventions were successful in reducing the diabetes incidence by 
30%-60% among participants with IGT (Pan et al. 1997; Knowler et al. 2002; Chan et al. 2009; 
Tuomilehto et al. 2001). However, weight loss accompanied most of the interventions, unlike in 
the current setting. One study assessed sustainability of the intervention after 10 years and 
found no long-term effectiveness (Diabetes Prevention Program Research Group et al. 2009). 
No data are available for prevention programs including participants with IFG or pre-diabetic 
HbA1c (Yudkin et al. 2014).  
 
5.3 Framework of diabetes  
The author of the current dissertation modified the conceptual framework model of 
malnutrition by UNICEF (1990) (Figure 25, p. 90). The framework model of malnutrition 
visualizes basic, underlying, and immediate causes of malnutrition, which lead to a 
manifestation of malnutrition. These causes are linked to various levels, ranging from the 
societal level (basic causes), to the household and community level (underlying causes) toward 
the individual level (immediate causes). 
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Figure 25 Conceptual framework of malnutrition (UNICEF 1990) 
This model was adapted according to the results of the current and other studies, and 
observations of the study area to conceptualize causes, problems, and challenges linked to type 
2 diabetes mellitus (Figure 26, p. 91). In the following, only findings related to the current 
research project are described. The research study among diabetic patients at KCMC identified a 
lack of sufficient health personnel, medical treatment, and diabetes knowledge among 
participants. Medical insurance that covered the costs for diabetes care was only available for 
50% of interviewed patients. Thus, payment for diabetes treatment imposes a burden on 
diabetic patients and may influence outcomes of diabetes care. All these findings are examples 
of basic and underlying causes and challenges.  
 A study conducted in 2012 among urban residents of Moshi revealed food intakes high 
in refined carbohydrates and fatty foods, combined with a sedentary lifestyle (Ludwig et al. 
2013). During the recruitment procedure for the dietary intervention study in 2013, high rates 
of pre-diabetes, undiagnosed diabetes, high glycemic levels among treated diabetes patients, 
obesity, and hypertension were detected. These findings are examples of the immediate 
challenges and causes of type 2 diabetes mellitus. To tackle the manifestation of type 2 diabetes 
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mellitus in this research area, multi-faced approaches with collaborations and efforts on the 
different levels along the conceptual framework are needed. 
 
 
Figure 26 Conceptual framework of diabetes mellitus, adapted from (UNICEF 1990) 
 
5.4 Limitations  
The study population was selected for a dietary intervention study using a particular 
recruitment procedure, such that it was not representative of the project region or the whole of 
Tanzania. Because the screening was tailored to include overweight and obese people, 
conclusions cannot be drawn about the overall population. However, the results provide 
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insights into health-related issues that should be further assessed and addressed. Most 
measurements were only performed once, and there was no measurement of IGT to compare 
to FPG levels. The measurement of FPG was an easy and accepted method of assessing glycemic 
status in this setting. The point-of-care device used did not require electricity or extensive 
training of health staff. Zhao et al. demonstrated that the measurement of glycemic status using 
a capillary blood sample is a feasible screening method in a low-resource setting (Zhao et al. 
2012). If FPG cannot be measured, RBG may be measured instead. Studies have demonstrated 
that a single RBG measurement of >100 mg/dL (Bowen et al. 2015) or >125 mg/dL (Ziemer et al. 
2008) were good predictors of diabetes. As HbA1c values had to be corrected afterwards, the 
results should be interpreted cautiously. During the pre-screening, BP was not assessed after 
five minutes rest, after which values might be lower. However, values were comparable to 
national data. This study was not designed as a screening for diabetes, but did detect high levels 
of undiagnosed diabetes. Further research is needed to analyze costs and benefits of screening 
activities in that region.  
 The current intervention study had several limitations. Not all participants were 
classified as IFG at their baseline assessment, which may have affected the glucose-lowering 
effect of bitter gourd. Although the study was a cross-over designed trial to reduce between-
subject variability, the within-subject variability may have influenced the study outcomes. The 
detected period effect affected the statistical analyses and the sample size had to be 
recalculated. Although only 52 participants finished the study and only 44 venous blood samples 
were analyzed for the primary outcome, the final sample size achieved a power of 0.82 
(according to a two-sample t-test) and statistical tests revealed a treatment difference despite 
the presence of a period effect. The food variety score calculated in the current study only 
includes information about food items consumed over the previous month, but not on the 
frequencies of consumption, which may have been modified. However, results of the regular 
checkup questionnaires showed that food intakes were mostly changed due to business trips or 
festivities. An influence of the medications taken by some participants prior to venous blood 
sampling on outcome parameters cannot be ruled out.  
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5.5 Conclusion and Outlook  
The current study aimed to assess anti-diabetic effects of 2.5 g raw dry bitter gourd powder 
among pre-diabetic participants in Moshi, Tanzania. The recruitment procedure to identify pre-
diabetic participants had an enrollment rate of 16% among people with a BMI of 27-35 kg/m² 
and an age of 30-65 years. The low concordance between FPG and HbA1c values detected during 
screening needs further investigation, as well as the discrepancy between ADA and WHO 
definitions of IFG. Screening activities showed high rates of obesity, undiagnosed hypertension, 
and undiagnosed diabetes cases, which require further investigation and call for an 
establishment of health programs. Identified risk factors for increased FPG were age, WC, BMI, 
and having a family member with diabetes. The visited working areas and other settings were all 
receptive to health-related issues, which should be utilized for health promotion activities and 
education.  
 After the dietary intervention study, there was a significant treatment difference 
between the bitter gourd and placebo groups with a decrease of FPG in the bitter gourd and 
and increase in the placebo group. This treatment difference is based on the change of FPG 
between baseline and endline. The glucose lowering effect of bitter gourd was higher among 
participants who started with higher levels of baseline FPG. As the current study included pre-
diabetic participants, the glucose-lowering effect of bitter gourd may be even more effective 
among diabetic participants. There were no further significant differences in other outcome 
variables between treatment groups.  
 In the overall study group, there was a significant reduction in FPG levels and systolic BP 
values between screening and baseline. This change might be due to a behavior change, as 
advice on a healthy lifestyle was provided during the screening, if requested by participants. The 
low dropout rate of 15% during the six-month study period underlines the interest in health and 
well-being. In conclusion, the consumption of 2.5 g dry bitter gourd (equivalent to 50 g fresh 
bitter gourd) in combination with education on a healthy lifestyle may be effective to lower 
raising blood glucose levels in the region and to prevent the progression of pre-diabetes to type 
2 diabetes mellitus. However, bitter gourd consumption is not recommended for pregnant and 
lactating women as well as people with G6PD deficiency.  
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Summary 
Prevalence of pre-diabetes and type 2 diabetes mellitus are on the rise not only in high-income 
countries, but also in low- and middle-income countries such as the United Republic of 
Tanzania, whereas many diabetes cases remain undiagnosed. Type 2 diabetes is often linked to 
overweight and obesity due to excess caloric intakes and sedentary lifestyles. In Tanzania, the 
most recent estimated prevalence of pre-diabetes was 9.1% (in 2013) and of diabetes 3.5% (in 
2015). Access to proper diabetes care and management is often insufficient in Tanzania. The 
increasing rates of diabetes will amplify the already existent burden on affected individuals and 
the country on its own. Alternative strategies such as the use of anti-diabetic plants, may be one 
possibility to fight against rising blood glucose levels and prevent the onset of type 2 diabetes 
mellitus. One medicinal plant with hypoglycemic effects is Momordica charantia, also known as 
bitter gourd or bitter melon. Bitter gourd has shown anti-diabetic effects in cell, animal, and 
human studies, but no clear recommendation on the application of bitter gourd variety, dosage, 
and mean of consumption is available. Bitter gourd is most commonly cultivated and consumed 
in Asian countries. Bitter gourd is also available in Sub-Saharan countries, mainly collected from 
the wild. The current research project was divided into two studies which were conducted in 
Moshi, Tanzania, between 2011-2014. The first study aimed to assess knowledge and usage of 
bitter gourd as well as knowledge and management of diabetes among diabetic patients. The 
second study aimed to assess anti-diabetic effects of 2.5 g dry raw bitter gourd powder 
consumption per day among pre-diabetics.  
 The first study was a cross-sectional survey with structured and open-ended questions 
and conducted at the Kilimanjaro Christian Medical Centre in Moshi, in 2011. Out of 155 
patients interviewed, 7% had heard about bitter gourd before, whereas 5% used it as a 
medicinal plant in adjunct to oral anti-diabetic drugs (OAD). Although bitter gourd was not well 
known, bitter tasting plants were consumed by almost all participants and around 50% stated to 
apply medicinal plants for various conditions. Symptoms were perceived between months and 
years before diagnosis. In regard to diabetes knowledge, symptoms were most known among 
patients followed by complications and causes. Almost all were on medical treatment, either on 
OAD, or insulin, or a combinations of both. Complications such as impaired sight and impotence 
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were stated by the patients. Around 90% stated to have changed their lifestyle after diagnosis 
toward higher intakes of vegetables and increased physical activity.  
 The second study was a cross-over designed, randomized, placebo-controlled, single-
blind, dietary intervention trial among pre-diabetic participants in 2013/14. It was conducted at 
the Kilimanjaro Clinical Research Institute in Moshi and included two eight-week intervention 
periods, separated by a four week washout period. Fasting plasma glucose (FPG), HbA1c, blood 
pressure (BP), and blood lipids were main assessed outcomes. Participants were recruited with 
the help of a pre-screening and screening phase in 2013. The following main inclusion criteria 
were applied: FPG 5.6-7 mmol/L, HbA1c 5.7-7.5%, BMI 27-35 kg/m², BP 90/60-160/110 mmHg, 
age 30-65 years, no clinically diagnosed diseases, no pregnancy or breastfeeding among women.  
 A total of 1256 people were pre-screened, and 382 who fit age and BMI criteria were 
further screened. Around 35% of screened people had pre-diabetic FPG values. After assessing 
all inclusion criteria, 61 participants (54% female, 46% male) started the intervention study. 
After the study duration of six months, the dropout rate was 15% with 52 participants finishing 
the study. Statistical analysis with a general linear mixed model revealed a period, but no carry-
over effect. The change of FPG levels significantly differed (p=0.01) between the bitter gourd 
and placebo groups, with a mean decrease in the bitter gourd (-0.2 mmol/L) and mean increase 
in the placebo group (0.1 mmol/L). Change of FPG was greater among participants with a higher 
baseline FPG. Other outcomes did not differ significantly. However, in the overall study group, 
there was a significant decrease of FPG and BP from the time of the screening (July-October 
2013) until the start of the intervention study (October 2013).  
 In conclusion, the first study showed a positive attitude toward the use of medicinal 
plants. However, in case of bitter gourd, usage and knowledge were very low. As symptoms of 
diabetes were present a relatively long time before diagnosis, diabetes knowledge of diabetic 
patients was presumably gained after diagnosis with the help of health staff and information 
posters displayed in the clinic. In addition, diabetes care imposed extra burdens on some 
participants. The existence of complications shows the need to improve diabetes management, 
including possibilities to monitor long-term glucose levels. 
 The recruitment procedure of the second study revealed high rates of diagnosed and 
undiagnosed diabetes. The intervention study demonstrated a blood glucose lowering effect of 
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daily bitter gourd consumption among pre-diabetics. The change of FPG prior to the study may 
be attributable to a behavior change after the screening. A combination of healthy lifestyle 
counseling and use of bitter gourd (with exception for pregnant or lactating women, and people 
with glucose-6-phosphatase-dehydrogenase deficiency) may be a feasible strategy to reduce 
blood glucose levels in that area.  
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Zusammenfassung 
Die Prävalenz von Prädiabtetes und Typ 2 Diabetes mellitus steigt nicht nur in einkommens-
starken, sondern auch in niedrig- und mitteleinkommensstarken Ländern, wie Tansania. Dabei 
sind viele der Diabetesfälle noch nicht diagnostiziert. Typ 2 Diabetes wird häufig in einen 
Zusammenhang mit Übergewicht und Adipositas gebracht, welches durch eine überschüssige 
Kalorieneinnahme und einen bewegungsarmen Lebensstil bedingt sein kann. Die neueste 
geschätzte Diabetesprävalenz Tansanias aus dem Jahr 2015 lag bei 3,5% und die neueste 
geschätzte Prädiabetesprävalenz aus dem Jahr 2013 bei 9,1%. In Tansania ist der Zugang zur 
Fürsorge und Behandlung von Diabetes unzureichend. Zunehmende Prävalenzen an Prädiabetes 
und Diabetes verstärken die schon bestehende Belastung Betroffener und des Landes in Bezug 
auf die Bekämpfung der Erkrankung. Alternative Strategien, wie die Anwendung anti-
diabetischer Pflanzen, könnte einen Ansatz darstellen, um präventiv steigenden 
Blutglucosewerten und den Ausbruch von Diabetes entgegen zu wirken. Eine solche Pflanze mit 
anti-diabetischen Wirkungen stellt Momordica charantia dar. Sie ist u.a. auch als Bittergurke 
oder Bittermelone bekannt. Die hypoglykämischen Wirkungen der Bittergurke wurden in vielen 
Zell-, Tier- und Humanstudien gezeigt. Bis heuten liegen aber noch keine genauen 
Empfehlungen über die Nutzung der Bittergurke und Dosierung dieser zur Blutzuckerkontrolle 
vor. Bittergurke wird vor allem in asiatischen Ländern kultiviert und verzehrt. In Ländern 
Subsahara Afrikas wird Bittergurke häufig als Wildpflanze gesammelt und konsumiert. Das 
vorliegende Forschungsprojekt war in zwei Studien gegliedert und wurde in Moshi Tansania 
durchgeführt. Die erste Studie zielte darauf ab, das Wissen und den Gebrauch der Bittergurke 
sowie das Wissen über und die Behandlung von Diabetes bei Diabetespatienten zu untersuchen. 
Das Ziel der zweiten Studie war, die anti-diabetische Wirkungen von 2,5 g roher getrockneter 
und pulverisierter Bittergurke unter Prädiabetikern zu untersuchen.  
Die erste Studies stellte eine Querschnittserhebung mit standardisierten Fragebögen 
(strukturierte und offene Fragegestellungen) dar und wurde 2011 am Kilimanjaro Christian 
Medical Centre in Moshi durchgeführt. Von den 155 befragten Patienten, kannten 7% die 
Bittergurke und 5% nutzten diese bereits als medizinisches Mittel zusätzlich zu ihrer normalen 
Medikation. Obwohl wenige der Befragten die Bittergurke kannten, verzehrten fast alle 
Zusammenfassung 
 
99 
 
Studienteilnehmer bitter schmeckende Pflanzen und ca. 50% der Befragten wandten bereits 
Phytomedizin an. Bei vielen zeigten sich Symptome Monate und Jahre vor der Bekanntgabe der 
Diagnose. In Bezug auf das Wissen über Diabetes stellte sich heraus, dass die Befragten ein 
höheres Wissen über Symptome der Diabeteserkrankung hatten als über Komplikationen und 
Ursachen von Diabetes. Fast alle der Patienten waren unter medikamentöser Behandlung, 
entweder mit oralen anti-diabetischen Medikamenten, Insulin oder einer Kombination aus 
beiden. Genannte Komplikationen der Patienten waren verminderte Sehstärke, Impotenz und 
Bluthochdruck. Ungefähr 90% der Befragten gaben an, dass sie nach der Feststellung der 
Diagnose ihren Lebensstil hin zu höherem Gemüsekonsum und gesteigerter körperlicher 
Aktivität geändert hatten.  
Die zweite Studie war eine cross-over, randomisierte, placebokontrollierte, einzeln verblindete, 
Ernährungsinterventionsstudie unter Prädiabetikern in 2013/14. Die Studie fand am Kilimanjaro 
Clinical Research Institute in Moshi, Tansania, statt und gliederte sich in zwei 
Interventionsphasen bestehend aus je acht Wochen. Die zwei Interventionsphasen waren durch 
eine vierwöchige Auswaschphase voneinander getrennt. Untersuchte Hauptuntersuchungs-
parameter waren Nüchternblutglucose (NBG), glycolisiertes Hämoglobin (HbA1c), Blutdruck und 
Blutlipide. Der Studie entsprechende Probanden wurden mit Hilfe eines zweistufigen Screenings 
im Jahr 2013 rekrutiert. Haupteinschlusskriterien waren: ein NBG von 5,6-6,9 mmol/L, ein HbA1c 
von 5,7-7,5%, ein BMI von 27-35 kg/m², ein Blutdruck von 90/60-160/110 mmHg, ein Alter von 
30-65 Jahren, keine klinisch diagnostizierte Erkrankung und keine vorliegende Schwangerschaft 
oder Stillzeit bei Frauen.  
Insgesamt wurden 1256 Personen auf ihren passenden BMI und ihr passendes Alter untersucht. 
Von diesen hatten wiederum 382 der Studie entsprechende BMI- und Alterswerte und wurden 
auf die verbleibenden Einschlusskriterien überprüft. Ca. 35% der untersuchten Probanden 
wiesen eine prädiabetische NBG auf. Nach Überprüfung der verbleidenden Kriterien, wurden 61 
Probanden, davon 54% weiblich, in die Studie aufgenommen. Nach sechsmonatiger 
Studiendauer lag die Dropoutrate bei 15% und somit beendeten 52 Probanden die Studie. Die 
statistische Analyse mittels eines allgemeinen linearen Modells zeigte einen Periodeneffekt, 
aber keinen carry-over Effekt. Die Veränderung des NBG war signifikant unterschiedlich (p=0,01) 
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zwischen der Bittergurken- und der Placebogruppe mit einem mittleren Abfall der NBG in der 
Bittergurkengruppe (-0,21 mmol/L) und einem mittleren Anstieg in der Placebogruppe (0,10 
mmol/L). Eine höhere Senkung der NBG war bei Probanden, die mit einer höheren NBG die 
Studie begonnen hatten, zu erkennen. Die anderen Parameter unterschieden sich nicht 
signifikant zwischen den Behandlungsgruppen. Im Hinblick auf das gesamte Studienkolletiv der 
52 Probanden zeigte sich bereits nach dem Zeitpunkt des Screenings während der 
Rekrutierungsphase (Juli bis Oktober 2013) und dem Beginn der Studie (Oktober 2013) ein 
signifikanter Abfall der NBG und des Blutdruckes.  
Schlussfolgernd zeigte die erste Studie eine positive Einstellung der Studienteilnehmer 
gegenüber der Nutzung von Phytomedizin, auch wenn das Wissen und der Gebrauch der 
Bittergurke gering waren. Da Symptome bereits eine längere Zeit vor der Feststellung der 
Diagnose bei den Patienten vorhanden waren, ist das Wissen über eine Diabeteserkrankung 
vermutlich erst nach der Diagnose mittels Informationsposter in den Untersuchungsräumen 
erworben worden.  Die Behandlung von Diabetes und damit verbundenen Kosten stellte für 
einige der Patienten eine zusätzliche Belastung dar. Diese Ergebnisse und das Vorhandensein 
von Komplikationen des Diabetes zeigen auf, dass es einen Bedarf gibt, Fürsorge und 
Behandlung von Diabetes zu verbessern.  
Die zweite Studie wies einen Glucose-senkenden Effekt der Bittergurke bei täglicher Einnahme 
unter Prädiabetikern auf. Die Reduzierung der NBG vor der Studie ist womöglich auf einen 
Lebensstilwandel zurückzuführen, da die Probanden auf Nachfrage hin, Informationen 
bezügliche eines gesunden Lebensstiles erhalten hatten. Eine Kombination aus Bildung über 
einen gesunden Lebensstil und der Nutzung der Bittergurke könnte eine realisierbare Strategie 
darstellen, um steigende Blutglucosewerte in dieser Region Tansanias zu bekämpfen. Eine 
Einnahme der Bittergurke sollte allerdings nicht bei Schwangeren, Stillenden oder Personen mit 
einer Glucose-6-Phosphatdehydrogenase-Mangel empfohlen werden.  
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Table D: Major recommendations on nutrition for diabetic patients (Franz et al. 2002) 
Carbohydrates Grading 
 
Foods containing carbohydrate from whole grains, fruits, vegetables, and low-fat 
milk are important components and should be included in a healthy diet. 
A 
 
With regard to the glycemic effects of carbohydrates, the total amount of 
carbohydrate in meals or snacks is more important than the source or type. 
 
A 
 
Because sucrose does not increase glycemia to a greater extent than isocaloric 
amounts of starch, sucrose and sucrose-containing foods do not need to be 
restricted by people with diabetes, however, they should be substituted for other 
carbohydrate sources or, if added, be covered with insulin or other glucose-
lowering medication. 
 
A 
 
Nonnutritive sweeteners are safe when consumed within the ADI levels established 
by the FDA. 
 
A 
 
Individuals receiving intensive insulin therapy should adjust their premeal insulin 
dosages based on the carbohydrate content of meals. 
 
B 
 
Although the use of low–glycemic index foods may reduce postprandial 
hyperglycemic, there is not sufficient evidence of long-term benefit to recommend 
use of low-glycemic index diets as a primary strategy in food/meal planning. 
 
B 
 
As far the general public, consumption of dietary fiber is to be encouraged; 
however, there is no reason to recommend that people with diabetes consume a 
greater amount of fiber than other Americans. 
 
B 
 
Individuals receiving fixed daily insulin dosages should try to be consistent in day-
to-day carbohydrate intake. 
 
C 
 
Carbohydrate and monounsaturated fat should together provide 60–70% of energy 
intake. However, the individual’s metabolic profile and need for weight loss should 
be considered when determining the monounsaturated fat content of the diet. 
 
E 
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Table D continued: Major recommendations on nutrition for diabetic patients (Franz et al. 2002) 
Protein Grading 
 
In individuals with controlled type 2 diabetes, ingested protein does not increase 
plasma glucose concentrations, although ingested protein is just as potent a 
stimulant of insulin secretion as carbohydrate. 
 
B 
 
For persons with diabetes, especially those not with less-than-optimal glucose 
control, the protein requirements may be greater than the RDA, but not greater 
than usual intake. 
 
B 
 
For individuals with diabetes, there is no evidence to suggest that usual protein 
intake (15–20% of total daily energy) should be modified if renal function is normal. 
 
E 
 
The long-term effects of diets high in protein and low in carbohydrate are unknown. 
Although such diets may produce short-term weight loss and improved glycemia, it 
has not been established that weight loss is maintained long-term. The  
long-term effect of such diets on LDL cholesterol is also a concern. 
 
E 
 
Fat 
 
In all, <10% of energy intake should be derived from saturated fats. Some individuals 
(i.e., those with LDL cholesterol ≥100 mg/dl) may benefit from lowering saturated fat 
intake to <70% of energy intake. 
A 
 
Dietary cholesterol intake should be <300 mg/day. Some individuals (i.e., those with 
LDL cholesterol ≥100 mg/dl) may benefit from lowering dietary cholesterol to <200 
mg per day. 
 
A 
 
To lower LDL cholesterol, energy derived from saturated fat can be reduced if weight 
loss is desirable or replaced with either carbohydrate or monounsaturated fat if 
weight loss is not a goal. 
 
B 
 
Intake of transunsaturated fatty acids should be minimized. 
 
B 
 
Reduced-fat diets when maintained long term contribute to modest loss of weight 
and improvement in dyslipidemia. 
 
B 
 
Polyunsaturated fat intake should be ׽10% of energy intake 
 
C 
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Table D continued: Major recommendations on nutrition for diabetic patients (Franz et al. 2002) 
Energy balance and obesity Grading 
 
In insulin-resistant individuals, reduced energy intake and modest weight loss 
improve insulin resistance and glycemia in the short-term. 
 
A 
 
Structured programs that emphasize lifestyle changes including education, reduced 
fat (<30% of daily energy) and energy intake, regular physical activity, and regular 
participant contact, can produce long-term weight loss on the order of 5 to 7% of 
starting weight. 
 
A 
 
Exercise and behavior modification are most useful as adjuncts to other weight-loss 
strategies. Exercise is helpful in maintenance of weight loss. 
 
A 
 
Standard weight-reduction diets, when used alone, are unlikely to produce long-
term weight loss. Structured, intensive lifestyle programs are necessary. 
 
A 
 
Micronutrients 
 
 
There is no clear evidence of benefit from vitamin or mineral supplementation in 
people with diabetes who do not have underlying deficiencies. Exceptions include 
folate for prevention of birth defects and calcium for prevention of bone disease. 
 
B 
 
Routine supplementation of the diet with antioxidants is not advised because of 
uncertainties related to long-term efficacy and safety. 
 
B 
 
Alcohol 
 
 
If individuals choose to drink alcohol, daily intake should be limited to one drink for 
adult women and two drinks for adult men. One drink is defined as a 12-oz beer, a 5-
oz glass of wine, or 1.5-oz glass of distilled spirits. 
 
B 
 
To reduce risk of hypoglycemia, alcohol should be consumed with food. 
 
B 
Scientific principles ranked based on the American Diabetes Association grading system. The 
highest ranking, A, is assigned when there is supportive evidence from multiple, well-conducted 
studies; B is an intermediate rating; C is a lower ranking; and E represents recommendations 
based on expert consensus. 
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